

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number
WO 02/081443 A1

(51) International Patent Classification⁷: **C07D 209/02**,
209/44, 209/46, 209/48, 217/22, 235/24, 235/28, 277/62,
403/02, A61K 31/47, 31/425, 31/415, 31/40, A61P 7/00

(21) International Application Number: PCT/US02/10965

(22) International Filing Date: 8 April 2002 (08.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/282,847 9 April 2001 (09.04.2001) US

(71) Applicant (for all designated States except US): **CHIRON CORPORATION** [US/US]; 4560 Horton Street,
Emeryville, CA 94608-2916 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHU, Daniel**

[—/US]; 3767 Benton Street, Santa Clara, CA 95051 (US).
BOYCE, Rustum, S. [IN/US]; Apartment No. 206, 1818
Broadway, San Francisco, CA 94109 (US). **DUHL, David**
[US/US]; 2720 Camino Lenada, Oakland, CA 94611 (US).
CHANG, Bryan [US/US]; Apartment J., 1235 Pine Creek
Way, Concord, CA 94520 (US).




(74) Agents: **LENTINI, David, P.** et al.; Chiron Corporation,
Intellectual Property - R338, P.O. Box 8097, Emeryville,
CA 94662-8097 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: NOVEL GUANIDINO COMPOUNDS



(57) Abstract: Compounds having the general structure I are provided. X and Y are independently selected from the group consisting of CH₂, N, NR⁹, C=O, C=S, S=O, SO₂, S, O, (CR⁶R⁷)_n, C(=O)-(CR⁶R⁷)_n, and C(=S)-(CR⁶R⁷)_n, where n is 1, 2, or 3. W is selected from the group consisting of (formula I) and L is selected from the group consisting of N, O, S=O, SO₂, C(O), NC(O), NC(S), OC(O), OC(S), C(NR¹⁰), C(NOR¹⁰), and a covalent bond. Z¹, Z², and Z³ are independently selected from the group consisting of substituted carbon and nitrogen. Compounds of formula I are agonists of the melanocortin-4 receptor ("MC-4r2) and therefore may have useful properties for controlling diseases related to MC-4r action in humans, such as obesity and type II diabetes.



European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*

5

NOVEL GUANIDINO COMPOUNDS

Cross-References to Related Applications

[0001] This application claims priority to U.S. Provisional Application No. 60/282,847 filed April 9, 2001, the entire disclosure of which is incorporated
10 herein by reference and for all purposes.

Field of the Invention

[0002] This invention relates to melanocortin-4 receptor (MC4-R) agonists and methods of their preparation. The invention also relates to methods of treating melanocortin-4 receptor-mediated diseases, such as
15 obesity or diabetes, by activating the melanocortin-4 receptor with compounds provided herein.

Background of the Invention

[0003] Melanocortins are peptide products resulting from post-translational processing of pro-opiomelanocortin and are known to have a
20 broad array of physiological activities. The natural melanocortins include the different types of melanocyte stimulating hormone (α -MSH, β -MSH, γ -MSH) and ACTH. Of these, α -MSH and ACTH are considered to be the main endogenous melanocortins.

[0004] The melanocortins mediate their effects through melanocortin
25 receptors (MC-R), a subfamily of G-protein coupled receptors. There are at least five different receptor subtypes (MC1-R to MC5-R). MC1-R mediates pigmentation of the hair and skin. MC2-R mediates the effects of ACTH on steroidogenesis in the adrenal gland. MC3-R and MC4-R are predominantly expressed in the brain. MC5-R is considered to have a role in the exocrine
30 gland system.

5 **[0005]** The melanocortin-4 receptor (MC4-R) is a seven-transmembrane
receptor. MC4-R may participate in modulating the flow of visual and sensory
information, coordinate aspects of somatomotor control, and/or participate in
the modulation of autonomic outflow to the heart. *Science* 1992 257:1248-125.
Significantly, inactivation of this receptor by gene targeting has resulted in mice
10 that develop a maturity onset obesity syndrome associated with hyperphagia,
hyperinsulinemia, and hyperglycemia. *Cell* 1997 Jan 10; 88(1): 131-41. MC4-R
has also been implicated in other disease states including erectile disorders,
cardiovascular disorders, neuronal injuries or disorders, inflammation, fever,
cognitive disorders, and sexual behavior disorders. Hadley M.E. and Haskell-
15 Luevano C., The proopiomelanocortin system. *Ann N Y Acad Sci*, 1999 Oct
20;885:1.

[0006] Furthermore, observations in connection with endogenous MCx-R
antagonists indicate that MC4-R is implicated in endogenous energy regulation.
For example, an agouti protein is normally expressed in the skin and is an
20 antagonist of the cutaneous MC receptor involved in pigmentation, MC1-R. M.
M. Ollmann *et al.*, *Science*, 278:135-138 (1997). However, overexpression of
agouti protein in mice leads to a yellow coat color due to antagonism of MC1-R
and increased food intake and body weight due to antagonism of MC4-R. L. L.
Kiefer *et al.*, *Biochemistry*, 36: 2084-2090 (1997); D. S. Lu *et al.*, *Nature*,
25 371:799-802 (1994). Agouti related protein (AGRP), an agouti protein
homologue, antagonizes MC4-R but not MC1-R. T. M. Fong *et al.*, *Biochem.*
Biophys. Res. Commun. 237:629-631 (1997). Administration of AGRP in mice
increases food intake and causes obesity but does not alter pigmentation. M.
Rossi *et al.*, *Endocrinology*, 139:4428-4431 (1998). Together, this research
30 indicates that MC4-R participates in energy regulation, and therefore, identifies
this receptor as a target for a rational drug design for the treatment of obesity.


[0007] In connection with MC4-R and its uncovered role in the etiology of
obesity and food intake, the prior art has reported compounds or compositions
that act as agonists or antagonists of MC4-R. As examples, U.S. Patent No.
35 6,060,589 describes polypeptides that are capable of modulating signaling
activity of melanocortin receptors. Also, U.S. Patent Nos. 6,054,556 and

- 5 5,731,408 describe families of agonists and antagonists for MC4-R receptors that are lactam heptapeptides having a cyclic structure.

[0008] There is a need to for potent and specific agonists of MC4-R that are low molecular weight non-peptide small molecules. Methods of treating a melanocortin-4 receptor mediated disease, such as obesity, with such non-peptide drugs, are also particularly desirable.

Summary of the Invention

[0009] The instant invention provides potent and specific agonists of MC4-R that are low molecular weight non-peptide small molecules. Thus, there has been provided, in accordance with one aspect of the invention, a compound of formula I:




wherein

[0010] X and Y are independently selected from the group consisting of CH₂, N, NR⁹, C=O, C=S, S=O, SO₂, S, O, (CR⁶R⁷)_n, C(=O)-(CR⁶R⁷)_n, and C(=S)-(CR⁶R⁷)_n;

[0011] n is 1, 2, or 3;

[0012] W is selected from the group consisting of



- 5 **[0013]** L is selected from the group consisting of N, O, S, S=O, SO₂, C(O), NC(O), NC(S), OC(O), OC(S), C(NR¹⁰), C(NOR¹⁰), and a covalent bond;
- [0014]** Z¹, Z², and Z³ are independently selected from the group consisting of CR⁸ and N;
- [0015]** R¹ is selected from the group consisting of H, and substituted and
10 unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclalkyl, cycloalkylalkyl, alkenyl, alkynyl, and alkyl groups;
- [0016]** R² is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkylalkyl, aryl, and arylalkyl groups;
- [0017]** R³ is selected from the group consisting of H, and substituted and
15 unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R² and R³ may join together to form a ring containing at least two N atoms;
- [0018]** R⁴ is selected from the group consisting of H, and substituted and
20 unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R² and R⁴ may join together to form a ring containing at least two N atoms;
- [0019]** R⁵ is selected from the group consisting of H, and substituted and
25 unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R⁴ and R⁵, together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R³ and R⁵ may join together to form a ring containing at least two N atoms;
- [0020]** R⁶ and R⁷ may be the same or different, and are each
30 independently selected from the group consisting of H, Cl, I, F, Br, OH, NH₂, CN, NO₂, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclalkylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl,

- 5 cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclaminocarbonyl, and heteroarylaminocarbonyl groups;

[0021] R^8 is independently selected from the group consisting of H, Cl, I, F, Br, OH, NH_2 , CN, NO_2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclamino, heteroarylmino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclaminocarbonyl, and heteroarylaminocarbonyl groups; and

10

[0022] R^9 and R^{10} are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocycl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, alkylcarbonyl, and arylcarbonyl groups.

15

[0023] Compounds provided by the invention further include prodrugs of the compound of formula I, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.

20

[0024] In one embodiment, X is CH_2 and Y is $C=O$.

[0025] In another embodiment, X is $C=O$ and Y is CH_2 .

[0026] In another embodiment, X is $C=O$ and Y is $C=O$.

[0027] In other embodiments, L is a covalent bond, and X and Y have the values according to any of the previous embodiments.

25

[0028] In another embodiment, Z^1 , Z^2 , and Z^3 are all CH, and X, Y, and L have the values according to any of the previous embodiments.

[0029] In another embodiment, at least one of Z^1 , Z^2 , or Z^3 is N, and X, Y, and L have the values according to any of the previous embodiments.

30 [0030] In another embodiment, X, Y, L, Z^1 , Z^2 , and Z^3 have any of the values of previous embodiments, and R^1 is selected from the group consisting

- 5 of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and heterocyclalkyl groups.

[0031] In another embodiment, X, Y, L, Z¹, Z², and Z³ have any of the values of previous embodiments, and R¹ is 2,4-disubstituted phenethyl.

- 10 [0032] In another embodiment, X, Y, L, Z¹, Z², and Z³ have any of the values of previous embodiments, and R¹ is selected from the group consisting of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.

- 15 [0033] In another embodiment, X, Y, L, Z¹, Z², and Z³ have any of the values of previous embodiments, and R¹ is selected from the group consisting of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4-methylphenethyl, 4-chlorophenethyl, 4-chlorobenzyl, 4-ethylphenethyl, cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl, 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolylethyl, 4-hydroxyphenethyl, and 3,4-dimethoxyphenethyl.

- 20 [0034] In another embodiment, X, Y, L, Z¹, Z², Z³, and R¹ have any of the values of previous embodiments, and R² is H.

- 25 [0035] In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocycl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups.

[0036] In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl groups.

- 30 [0037] In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2-dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5-

5 dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2-aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3-diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5-diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2-alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3-dialkoxycyclohexyl, 2,4-dialkoxycyclohexyl, 3,4-dialkoxycyclohexyl, 2,5-dialkoxycyclohexyl, 2,6-dialkoxycyclohexyl, 2,2-dialkoxycyclohexyl, 2-alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3-dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5-dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2-aryl cyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkyl norbornyl, bornyl, norbornyl, and decalinyl groups.

20 **[0038]** In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2-dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5-dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3-methylcyclohexyl, 4-methylcyclohexyl, cyclohex-3-enyl, 3,3,5-trimethylcyclohexyl, 4-*t*-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, 25 isopinocampheyl, 7,7-dimethylnorbornyl, 4-isopropylcyclohexyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, and 3-methylcycloheptyl.

[0039] In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, R², and R³ have 30 any of the values of previous embodiments, and R⁵ is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups.

[0040] In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, R², and R³ have 35 any of the values of previous embodiments, R⁴ is H, and R⁵ is selected from the

- 5 group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.

[0041] In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, R², and R³ have any of the values of previous embodiments, R⁴ is H, and R⁵ is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.


[0042] In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, R², and R³ have any of the values of previous embodiments, and R⁴ and R⁵ may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.

[0043] In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, R², and R³ have any of the values of previous embodiments, and R⁴ and R⁵ may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.

[0044] In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, R², and R³ have any of the values of previous embodiments, and R⁴ and R⁵, together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group.

[0045] In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, R², and R³ have any of the values of previous embodiments, and R⁴ and R⁵, together with the nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.

[0046] There has also been provided, in accordance with another aspect of the invention, a compound of formula II:




5 wherein

[0047] A is selected from the group consisting of C or CH;

[0048] X and Y are independently selected from the group consisting of CH₂, N, C=O, C=S, (CR⁶R⁷)_n, S=O, SO₂, O, NR⁹, S, C(=O)-(CR⁶R⁷)_n, and C(=S)-(CR⁶R⁷)_n;

10 **[0049]** n is 1, 2, or 3;

[0050] W is selected from the group consisting of



[0051] Z¹, Z², and Z³ are independently selected from the group consisting of CR⁸ and N;

15 **[0052]** L is selected from the group consisting of N, O, S, S=O, SO₂, C(O), NC(O), NC(S), OC(O), OC(S), C(NR¹⁰), C(NOR¹⁰), and a covalent bond;

[0053] R¹ is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heterocyclyl, cycloalkyl, heterocyclalkyl, cycloalkylalkyl, alkenyl, alkynyl, and alkyl groups;

20 **[0054]** R² is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkylalkyl, aryl, and arylalkyl groups;

[0055] R³ is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R²

25 and R³ may join together to form a ring containing at least two N atoms;

- 5 **[0056]** R^4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R^2 and R^4 may join together to form a ring containing at least two N atoms;
- 10 **[0057]** R^5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R^4 and R^5 , together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R^3 and R^5 may join together to form a ring containing at least two N atoms;
- 15 **[0058]** R^6 and R^7 may be the same or different, and are each independently selected from the group consisting of H, Cl, I, F, Br, OH, NH_2 , CN, NO_2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, 20 cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
- 25 **[0059]** R^8 is independently selected from the group consisting of H, Cl, I, F, Br, OH, NH_2 , CN, NO_2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups; and
- 30 **[0060]** R^9 and R^{10} are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, alkylcarbonyl, and arylcarbonyl groups.
- [0061]** Compounds provided by the invention further include prodrugs of the compound of formula II, pharmaceutically acceptable salts thereof,

- 5 stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.

[0062] In one embodiment, X is N, Y is NH, A is C, and the bond between X and A is a double bond.

- 10 [0063] In another embodiment, X is NH, Y is N, A is C, and the bond between Y and A is a double bond.

[0064] In another embodiment, A is C and the bond between either A and X or between A and Y is a double bond.

[0065] In another embodiment, X, Y, and A have any of the values of previous embodiments, and L is a covalent bond.

- 15 [0066] In another embodiment, X, Y, A, and L have any of the values of previous embodiments, and Z¹, Z², and Z³ are all CH.

[0067] In another embodiment, X, Y, A, and L have any of the values of previous embodiments, and at least one of Z¹, Z², or Z³ is N.

- 20 [0068] In another embodiment, X, Y, A, L, Z¹, Z², and Z³ have any of the values of previous embodiments, and R¹ is selected from the group consisting of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and heterocyclalkyl groups.

[0069] In another embodiment, X, Y, A, L, Z¹, Z², and Z³ have any of the values of previous embodiments, and R¹ is 2,4-disubstituted phenethyl.

- 25 [0070] In another embodiment, X, Y, A, L, Z¹, Z², and Z³ have any of the values of previous embodiments, and R¹ is selected from the group consisting of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.

- 30 [0071] In another embodiment, X, Y, A, L, Z¹, Z², and Z³ have any of the values of previous embodiments, and R¹ is selected from the group consisting of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4-methylphenethyl, 4-chlorophenethyl, 4-chlorobenzyl, 4-ethylphenethyl,

- 5 cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl, 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolyethyl, 4-hydroxyphenethyl, and 3,4-dimethoxyphenethyl.

[0072] In another embodiment, X, Y, A, L, Z¹, Z², Z³, and R¹ have any of the values of previous embodiments, and R² is H.

- 10 [0073] In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups.

- 15 [0074] In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl groups.

- [0075] In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2-dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5-dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2-aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3-diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5-diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2-alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3-dialkoxycyclohexyl, 2,4-dialkoxycyclohexyl, 3,4-dialkoxycyclohexyl, 2,5-dialkoxycyclohexyl, 2,6-dialkoxycyclohexyl, 2,2-dialkoxycyclohexyl, 2-alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3-dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5-dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2-
- 20
- 25
- 30

- 5 arylcyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkylnorbornyl, bornyl, norbornyl, and decalanyl groups.

- [0076] In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2-dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5-dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3-methylcyclohexyl, 4-methylcyclohexyl, cyclohex-3-enyl, 3,3,5-trimethylcyclohexyl, 4-*t*-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, 15 isopinocampheyl, 7,7-dimethylnorbornyl, 4-isopropylcyclohexyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, and 3-methylcycloheptyl.

- [0077] In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁵ is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, 20 aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups.

- [0078] In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, R⁴ is H, and R⁵ is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and 25 heteroarylalkyl groups.

- [0079] In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, R⁴ is H, and R⁵ is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4- 30 fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.


- [0080] In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁴ and R⁵ may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.

- 5 [0081] In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁴ and R⁵ may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 10 2-chlorobenzyl, and thiophene groups.

- [0082] In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁴ and R⁵, together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino 15 group.

- [0083] In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁴ and R⁵, together with the nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.

- 20 [0084] There has also been provided, in accordance with another aspect of the invention, a compound of formula III:



III

wherein

- [0085] X and Y are independently selected from the group consisting of 25 CH₂, N, C=O, NR⁹, C=S, S=O, SO₂, O, S, (CR⁶R⁷)_n, C(=O)-(CR⁶R⁷)_n, and C(=S)-(CR⁶R⁷)_n;

- [0086] D is selected from the group consisting of N, and C;

- [0087] If X is N, then Y is not N, but may be NH;

5 [0088] If Y is N, then X is not N, but may be NH;

[0089] If X is CH₂, then Y is not CH₂;


[0090] If Y is CH₂, then X is not CH₂;

[0091] If X is NH, then Y is not NH;

[0092] If Y is NH, then X is not NH;

10 [0093] L is selected from the group consisting of N, O, S, S=O, SO₂, C(O), NC(O), NC(S), OC(O), OC(S), C(NR¹⁰), C(NOR¹⁰), and a covalent bond;

[0094] W is selected from the group consisting of



[0095] Z¹, Z², and Z³ are independently selected from the group
15 consisting of CR⁸ and N;

[0096] R¹ is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclalkyl, cycloalkylalkyl, alkenyl, alkynyl, and alkyl groups;

[0097] R² is selected from the group consisting of H, and substituted and
20 unsubstituted alkyl, alkenyl, alkynyl, cycloalkylalkyl, aryl, and arylalkyl groups;

[0098] R³ is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R² and R³ may join together to form a ring containing at least two N atoms;

5 **[0099]** R^4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R^2 and R^4 may join together to form a ring containing at least two N atoms;

10 **[0100]** R^5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R^4 and R^5 , together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R^3 and R^5 may join together to form a ring containing at least two N atoms;

15 **[0101]** R^6 and R^7 may be the same or different, and are each independently selected from the group consisting of H, Cl, I, F, Br, OH, NH_2 , CN, NO_2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, 20 cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;

25 **[0102]** R^8 is independently selected from the group consisting of H, Cl, I, F, Br, OH, NH_2 , CN, NO_2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups; and

30 **[0103]** R^9 and R^{10} are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, alkylcarbonyl, and arylcarbonyl groups.

[0104] Compounds provided by the invention further include prodrugs of the compound of formula III, pharmaceutically acceptable salts thereof,

- 5 stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.

[0105] In one embodiment, **X** is CH₂, **Y** is C=O, and **D** is N.

[0106] In another embodiment, **X** is C=O, **Y** is CH₂, and **D** is N.

[0107] In another embodiment, **X** is C=O, **Y** is C=O, and **D** is N.

- 10 [0108] In another embodiment, **X** is N, **Y** is NH, **D** is C, and the bond between **X** and **D** is a double bond.

[0109] In another embodiment, **X** is NH, **Y** is N, **D** is C, and the bond between **Y** and **D** is a double bond.

- [0110] In another embodiment, **X**, **Y**, and **D** have any of the values of:
15 previous embodiments, and **L** is a covalent bond.

[0111] In another embodiment, **X**, **Y**, **D**, and **L** have any of the values of previous embodiments, and **Z**¹, **Z**², and **Z**³ are all CH.

[0112] In another embodiment, **X**, **Y**, **D**, and **L** have any of the values of previous embodiments, and at least one of **Z**¹, **Z**², or **Z**³ is N.

- 20 [0113] In another embodiment, **X**, **Y**, **D**, **L**, **Z**¹, **Z**², and **Z**³ have any of the values of previous embodiments, and **R**¹ is selected from the group consisting of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and heterocyclalkyl groups.

- [0114] In another embodiment, **X**, **Y**, **D**, **L**, **Z**¹, **Z**², and **Z**³ have any of the
25 values of previous embodiments, and **R**¹ is 2,4-disubstituted phenethyl.

[0115] In another embodiment, **X**, **Y**, **D**, **L**, **Z**¹, **Z**², and **Z**³ have any of the values of previous embodiments, and **R**¹ is selected from the group consisting of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.

- [0116] In another embodiment, **X**, **Y**, **D**, **L**, **Z**¹, **Z**², and **Z**³ have any of the
30 values of previous embodiments, and **R**¹ is selected from the group consisting

5 of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4-methylphenethyl, 4-chlorophenethyl, 4-chlorobenzyl, 4-ethylphenethyl, cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl, 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolyethyl, 4-hydroxyphenethyl, and 3,4-dimethoxyphenethyl.

10 **[0117]** In another embodiment, X, Y, D, L, Z¹, Z², Z³, and R¹ have any of the values of previous embodiments, and R² is H.

[0118] In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, 15 heteroaryl, heterocyclyl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups.

[0119] In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl 20 groups.

[0120] In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2-dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5-dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 25 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2-aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3-diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5-diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2-alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3-dialkoxycyclohexyl, 2,4-dialkoxycyclohexyl, 3,4-dialkoxycyclohexyl, 2,5-dialkoxycyclohexyl, 2,6-dialkoxycyclohexyl, 2,2-dialkoxycyclohexyl, 2-alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3-dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5-

- 5 dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2-aryl cyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkyl norbornyl, bornyl, norbornyl, and decalinyl groups.
- 10 **[0121]** In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2-dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5-dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3-
- 15 methylcyclohexyl, 4-methylcyclohexyl, cyclohex-3-enyl, 3,3,5-trimethylcyclohexyl, 4-*t*-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbornyl, 4-isopropylcyclohexyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, and 3-methylcycloheptyl.
- [0122]** In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, R² and R³ have
- 20 any of the values of previous embodiments, and R⁵ is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups.
- [0123]** In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, R² and R³ have
- 25 any of the values of previous embodiments, R⁴ is H, and R⁵ is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
- [0124]** In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, R² and R³ have
- any of the values of previous embodiments, R⁴ is H, and R⁵ is selected from the
- 30 group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
- [0125]** In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, R² and R³ have
- any of the values of previous embodiments, and R⁴ and R⁵ may be the same or

- 5 different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.

[0126] In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁴ and R⁵ may be the same or different and are each independently selected from the group consisting of
10 substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.

[0127] In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁴ and R⁵, together with the
15 nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group.

[0128] In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁴ and R⁵, together with the
20 nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.

[0129] There has also been provided, in accordance with another aspect of the invention, a composition comprising a compound according to the instant invention and a pharmaceutically acceptable carrier.

25 [0130] There has also been provided, in accordance with another aspect of the invention, a method of activating MC4-R, comprising administering to a subject in need thereof, an effective amount of a compound or composition of the instant invention.

[0131] There has also been provided, in accordance with another aspect
30 of the invention, a method of treating an MC4-R mediated disease, comprising administering to a subject in need thereof, a compound or composition of the instant invention.

5 **[0132]** In one embodiment, a disease to be treated by those methods of the instant invention is obesity, or type I or type II diabetes.

[0133] There has also been provided, in accordance with another aspect of the invention, a method of decreasing blood glucose levels, comprising administering to a subject in need thereof, a compound or composition of the
10 instant invention.

[0134] In various alternative embodiments, the composition is administered orally, rectally, by subcutaneous injection, by intravenous injection, by intramuscular injection, or by intraperitoneal injection.

[0135] Other objects, features and advantages of the present invention
15 will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this
20 detailed description.

Detailed Description of the Preferred Embodiment

[0136] The instant invention relates to novel classes of small molecule melanocortin-4 receptor (MC4-R) agonists. These compounds can be formulated into compositions and are useful in activating MC4-R, or in the
25 treatment of MC4-R-mediated diseases, such as obesity.

5 **[0137]** The following definitions are used throughout this specification:

[0138] **Alkyl groups** are straight chain lower alkyl groups having 1 to about 8 carbon atoms, as exemplified by methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl. Alkyl groups also include branched chain isomers of straight chain alkyl groups, including, but not limited to, isopropyl, sec-butyl, t-butyl, isopentyl and so on. Representative substituted alkyl groups may be substituted one or more times with, for example, amino, thio, alkoxy, or halo.

[0139] **Cycloalkyl groups** are cyclic alkyl groups such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups, and can include two or more bridgehead carbon atoms to form polycyclic rings (e.g., norbornyl or bicyclo[3.1.1]heptyl). Cycloalkyl groups also includes rings that are substituted with straight or branched chain alkyl groups as defined above (e.g., bornyl or 2,6,6-trimethylbicyclo[3.1.1]heptyl). Representative substituted cycloalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4- 2,5- or 2,6-disubstituted cyclohexyl groups or mono-, di- or tri-substituted norbornyl or cycloheptyl groups, which may be substituted with, for example, alkyl, alkoxy, amino, thio, or halo groups.

[0140] **Alkenyl groups** are straight chain, branched or cyclic lower alkyl groups having 2 to about 8 carbon atoms, and further including at least one double bond, as exemplified, for instance, by vinyl, propenyl, 2-butenyl, 3-butenyl, isobutenyl, cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, and hexadienyl groups among others.

[0141] **Alkynyl groups** are straight chain or branched lower alkyl groups having 2 to about 8 carbon atoms, and further including at least one triple bond, as exemplified by groups, including, but not limited to, ethynyl, propynyl, and butynyl groups.

[0142] **Aryl groups** are cyclic aromatic hydrocarbons that do not contain heteroatoms. Thus aryl groups include, but are not limited to, phenyl, azulene, heptalene, biphenylene, indacene, fluorene, phenanthrene, triphenylene,

- 5 pyrene, naphthacene, chrysene, biphenyl, anthracenyl, and naphthenyl groups. Although the phrase "aryl groups" includes groups containing fused rings, such as fused aromatic-aliphatic ring systems, it does not include aryl groups that have other groups, such as alkyl or halo groups, bonded to one of the ring members. Rather, groups such as tolyl are referred to as substituted aryl
- 10 groups. The phrase "aryl groups" includes groups bonded to one or more carbon atom(s), and/or nitrogen atom(s), in the compounds of formulas I and II. Representative substituted aryl groups may be mono-substituted or substituted more than once, such as, but not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or benzyl groups, which may be substituted with groups including, but
- 15 not limited to, amino, alkoxy, alkyl, or halo.

[0143] Cycloalkylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a cycloalkyl group as defined above.

- [0144] Arylalkyl groups** are alkyl groups as defined above in which a
- 20 hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above.

- [0145] Heterocyclyl groups** are nonaromatic ring compounds containing 3 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S. The phrase "heterocyclyl group"
- 25 includes fused ring species including those comprising fused aromatic and nonaromatic groups. However, the phrase does not include heterocyclyl groups that have other groups, such as alkyl or halo groups, bonded to one of the ring members. Rather, these are referred to as "substituted heterocyclyl groups". Heterocyclyl groups include, but are not limited to, piperazino,
- 30 morpholino, thiomorpholino, pyrrolidino, piperidino and homopiperazino groups. Representative substituted heterocyclyl groups may be mono-substituted or substituted more than once, such as, but not limited to morpholino or piperazino groups, which are 2-, 3-, 4-, 5-, or 6-substituted, or disubstituted with groups including, but not limited to, amino, alkoxy, alkyl, or halo.

5 **[0146]** **Heteroaryl groups** are aromatic ring compounds containing 3 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S. Heteroaryl groups include, but are not limited to, groups such as furan, thiophene, pyrrole, isopyrrole, diazole, imidazole, isoimidazole, triazole, dithiole, oxathiole, isoxazole, oxazole, thiazole, 10 isothiazole, oxadiazole, oxatriazole, dioxazole, oxathiazole, pyran, dioxin, pyridine, pyrimidine, pyridazine, pyrazine, triazine, oxazine, isoxazine, oxathiazine, azepin, oxepin, thiepin, diazepine, benzofuran, and isobenzofuran. Although the phrase "heteroaryl groups" includes fused ring compounds, the phrase does not include heteroaryl groups that have other groups bonded to 15 one of the ring members, such as alkyl groups. Rather, heteroaryl groups with such substitution are referred to as "substituted heterocyclyl groups". Representative substituted heterocyclyl groups may be substituted one or more times with groups including, but not limited to, amino, alkoxy, alkyl, or halo.

20 **[0147]** **Heterocyclylalkyl groups** are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heterocyclyl group as defined above.

[0148] **Heteroarylalkyl groups** are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined above.


25 **[0149]** **Aminocarbonyl groups** are groups of the formula $RR'NC(O)-$, wherein R or R' may be the same or different, and each is independently selected from H, or substituted or unsubstituted alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl groups, as defined above.

30 **[0150]** In general, "**substituted**" refers to a group as defined above in which one or more bonds to a hydrogen atom contained therein are replaced by a bond to non-hydrogen or non-carbon atoms such as, but not limited to, a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, aryloxy groups, and ester groups; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfone

- 5 groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as in trialkylsilyl groups, dialkylarylsilyl groups, alkylarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups. Substituted
- 10 alkyl groups and also substituted cycloalkyl groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom is replaced by a bond to a heteroatom such as oxygen in carbonyl, carboxyl, and ester groups; nitrogen in groups such as imines, oximes, hydrazones, and nitriles.

- [0151] Substituted cycloalkyl, substituted aryl, substituted heterocycl
- 15 and substituted heteroaryl also include rings and fused ring systems which may be substituted with alkyl groups as defined above. Substituted arylalkyl groups may be substituted on the aryl group, on the alkyl group, or on both the aryl and alkyl groups.

- [0152] The instant invention provides potent and specific agonists of
- 20 MC4-R that are low molecular weight non-peptide small molecules. Thus, there has been provided, in accordance with one aspect of the invention, a compound of formula I:




wherein

- 25 [0153] X and Y are independently selected from the group consisting of CH₂, N, NR⁶, C=O, C=S, S=O, SO₂, S, O, (CR⁶R⁷)_n, C(=O)-(CR⁶R⁷)_n, and C(=S)-(CR⁶R⁷)_n;

[0154] n is 1, 2, or 3;

[0155] W is selected from the group consisting of



[0156] L is selected from the group consisting of N, O, S, S=O, SO₂, C(O), NC(O), NC(S), OC(O), OC(S), C(NR¹⁰), C(NOR¹⁰), and a covalent bond;

[0157] Z¹, Z², and Z³ are independently selected from the group consisting of CR⁸ and N;

10 [0158] R¹ is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclalkyl, cycloalkylalkyl, alkenyl, alkynyl, and alkyl groups;

[0159] R² is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkylalkyl, aryl, and arylalkyl groups;

15 [0160] R³ is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R² and R³ may join together to form a ring containing at least two N atoms;

20 [0161] R⁴ is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R² and R⁴ may join together to form a ring containing at least two N atoms;

25 [0162] R⁵ is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R⁴ and R⁵, together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R³ and R⁵ may join together to form a ring containing at least two N atoms;

5 **[0163]** R^6 and R^7 may be the same or different, and are each independently selected from the group consisting of H, Cl, I, F, Br, OH, NH_2 , CN, NO_2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, 10 cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;

[0164] R^8 is independently selected from the group consisting of H, Cl, I, F, Br, OH, NH_2 , CN, NO_2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, 15 heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups; and

[0165] R^9 and R^{10} are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, 20 heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, alkylcarbonyl, and arylcarbonyl groups.

[0166] Compounds provided by the invention further include prodrugs of the compound of formula I, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or 25 solvates thereof.

[0167] In one embodiment, X is CH_2 and Y is C=O.

[0168] In another embodiment, X is C=O and Y is CH_2 .

[0169] In another embodiment, X is C=O and Y is C=O.

[0170] In other embodiments, L is a covalent bond, and X and Y have 30 the values according to any of the previous embodiments.

[0171] In another embodiment, Z^1 , Z^2 , and Z^3 are all CH, and X, Y, and L have the values according to any of the previous embodiments.

- 5 **[0172]** In another embodiment, at least one of Z^1 , Z^2 , or Z^3 is N, and X, Y, and L have the values according to any of the previous embodiments.
- [0173]** In another embodiment, X, Y, L, Z^1 , Z^2 , and Z^3 have any of the values of previous embodiments, and R^1 is selected from the group consisting of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and
- 10 heterocyclalkyl groups.
- [0174]** In another embodiment, X, Y, L, Z^1 , Z^2 , and Z^3 have any of the values of previous embodiments, and R^1 is 2,4-disubstituted phenethyl.
- [0175]** In another embodiment, X, Y, L, Z^1 , Z^2 , and Z^3 have any of the values of previous embodiments, and R^1 is selected from the group consisting
- 15 of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.
- [0176]** In another embodiment, X, Y, L, Z^1 , Z^2 , and Z^3 have any of the values of previous embodiments, and R^1 is selected from the group consisting of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4-methylphenethyl, 4-chlorophenethyl, 4-chlorobenzyl, 4-ethylphenethyl,
- 20 cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl, 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolyethyl, 4-hydroxyphenethyl, and 3,4-dimethoxyphenethyl.
- [0177]** In another embodiment, X, Y, L, Z^1 , Z^2 , Z^3 , and R^1 have any of the values of previous embodiments, and R^2 is H.
- 25 **[0178]** In another embodiment, X, Y, L, Z^1 , Z^2 , Z^3 , R^1 , and R^2 have any of the values of previous embodiments, and R^3 is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocycl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups.
- 30 **[0179]** In another embodiment, X, Y, L, Z^1 , Z^2 , Z^3 , R^1 , and R^2 have any of the values of previous embodiments, and R^3 is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl groups.

5 **[0180]** In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2-dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5-dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 10 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2-aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3-diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5-diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2-alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3-dialkoxycyclohexyl, 2,4-dialkoxycyclohexyl, 3,4-dialkoxycyclohexyl, 2,5-dialkoxycyclohexyl, 2,6-dialkoxycyclohexyl, 2,2-dialkoxycyclohexyl, 2-alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3-dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5-dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, 15 cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2-aryl cyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkyl norbornyl, bornyl, norbornyl, and decalinyl groups.

25 **[0181]** In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2-dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5-dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3-methylcyclohexyl, 4-methylcyclohexyl, cyclohex-3-enyl, 3,3,5-trimethylcyclohexyl, 4-*t*-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, 30 isopinocampheyl, 7,7-dimethylnorbornyl, 4-isopropylcyclohexyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, and 3-methylcycloheptyl.

35 **[0182]** In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, R², and R³ have any of the values of previous embodiments, and R⁵ is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl,

- 5 aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups.

[0183] In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, R², and R³ have any of the values of previous embodiments, R⁴ is H, and R⁵ is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and
10 heteroarylalkyl groups.

[0184] In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, R², and R³ have any of the values of previous embodiments, R⁴ is H, and R⁵ is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-
15 fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.

[0185] In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, R², and R³ have any of the values of previous embodiments, and R⁴ and R⁵ may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.


20 [0186] In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, R², and R³ have any of the values of previous embodiments, and R⁴ and R⁵ may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl,
25 2-chlorobenzyl, and thiophene groups.

[0187] In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, R², and R³ have any of the values of previous embodiments, and R⁴ and R⁵, together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino
30 group.

[0188] In another embodiment, X, Y, L, Z¹, Z², Z³, R¹, R², and R³ have any of the values of previous embodiments, and R⁴ and R⁵, together with the

- 5 nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.


[0189] There has also been provided, in accordance with another aspect of the invention, a compound of formula II:



II

wherein

- 10 **[0190]** A is selected from the group consisting of C or CH;
- [0191]** X and Y are independently selected from the group consisting of CH₂, N, C=O, C=S, (CR⁶R⁷)_n, S=O, SO₂, O, NR⁹, S, C(=O)-(CR⁶R⁷)_n, and C(=S)-(CR⁶R⁷)_n;
- [0192]** n is 1, 2, or 3;
- 15 **[0193]** W is selected from the group consisting of



[0194] Z¹, Z², and Z³ are independently selected from the group consisting of CR⁸ and N;

- [0195]** L is selected from the group consisting of N, O, S, S=O, SO₂,
 20 C(O), NC(O), NC(S), OC(O), OC(S), C(NR¹⁰), C(NOR¹⁰), and a covalent bond;

- 5 **[0196]** R^1 is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkylalkyl, alkenyl, alkynyl, and alkyl groups;
- [0197]** R^2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkylalkyl, aryl, and arylalkyl groups;
- 10 **[0198]** R^3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R^2 and R^3 may join together to form a ring containing at least two N atoms;
- [0199]** R^4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R^2 and R^4 may join together to form a ring containing at least two N atoms;
- 15 **[0200]** R^5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R^4 and R^5 , together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R^3 and R^5 may join together to form a ring containing at least two N atoms;
- 20 **[0201]** R^6 and R^7 may be the same or different, and are each independently selected from the group consisting of H, Cl, I, F, Br, OH, NH_2 , CN, NO_2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
- 30 **[0202]** R^8 is independently selected from the group consisting of H, Cl, I, F, Br, OH, NH_2 , CN, NO_2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino,

- 5 heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups; and

[0203] R^9 and R^{10} are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl,
10 heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, alkylcarbonyl, and arylcarbonyl groups.

[0204] Compounds provided by the invention further include prodrugs of the compound of formula II, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or
15 solvates thereof.

[0205] In one embodiment, X is N, Y is NH, A is C, and the bond between X and A is a double bond.

[0206] In another embodiment, X is NH, Y is N, A is C, and the bond between Y and A is a double bond.

20 [0207] In another embodiment, A is C and the bond between either A and X or between A and Y is a double bond.

[0208] In another embodiment, X, Y, and A have any of the values of previous embodiments, and L is a covalent bond.

[0209] In another embodiment, X, Y, A, and L have any of the values of
25 previous embodiments, and Z^1 , Z^2 , and Z^3 are all CH.

[0210] In another embodiment, X, Y, A, and L have any of the values of previous embodiments, and at least one of Z^1 , Z^2 , or Z^3 is N.

[0211] In another embodiment, X, Y, A, L, Z^1 , Z^2 , and Z^3 have any of the values of previous embodiments, and R^1 is selected from the group consisting
30 of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and heterocyclylalkyl groups.

- 5 **[0212]** In another embodiment, X, Y, A, L, Z¹, Z², and Z³ have any of the values of previous embodiments, and R¹ is 2,4-disubstituted phenethyl.
- [0213]** In another embodiment, X, Y, A, L, Z¹, Z², and Z³ have any of the values of previous embodiments, and R¹ is selected from the group consisting of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.
- 10 **[0214]** In another embodiment, X, Y, A, L, Z¹, Z², and Z³ have any of the values of previous embodiments, and R¹ is selected from the group consisting of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4-methylphenethyl, 4-chlorophenethyl, 4-chlorobenzyl, 4-ethylphenethyl, cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl,
- 15 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolyethyl, 4-hydroxyphenethyl, and 3,4-dimethoxyphenethyl.
- [0215]** In another embodiment, X, Y, A, L, Z¹, Z², Z³, and R¹ have any of the values of previous embodiments, and R² is H.
- [0216]** In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, and R² have
- 20 any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups.
- [0217]** In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, and R² have
- 25 any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl groups.
- [0218]** In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, and R² have
- 30 any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2-dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5-dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl, 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2-


5 aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3-diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5-diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2-alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3-dialkoxycyclohexyl, 2,4-dialkoxycyclohexyl, 3,4-dialkoxycyclohexyl, 2,5-
 10 dialkoxycyclohexyl, 2,6-dialkoxycyclohexyl, 2,2-dialkoxycyclohexyl, 2-alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3-dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5-dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl, cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2-
 15 arylcyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkylnorbornyl, bornyl, norbornyl, and decalinyl groups.

[0219] In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group
 20 consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2-dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5-dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3-methylcyclohexyl, 4-methylcyclohexyl, cyclohex-3-enyl, 3,3,5-trimethylcyclohexyl, 4-*t*-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl,
 25 isopinocampheyl, 7,7-dimethylnorbornyl, 4-isopropylcyclohexyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, and 3-methylcycloheptyl.

[0220] In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁵ is selected from the group
 30 consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups.

[0221] In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, R⁴ is H, and R⁵ is selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and
 35 heteroarylalkyl groups.

- 5 **[0222]** In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, R⁴ is H, and R⁵ is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
- 10 **[0223]** In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁴ and R⁵ may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.
- 15 **[0224]** In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁴ and R⁵ may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.
- 20 **[0225]** In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁴ and R⁵, together with the nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group.
- 25 **[0226]** In another embodiment, X, Y, A, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁴ and R⁵, together with the nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.
- 30 **[0227]** There has also been provided, in accordance with another aspect of the invention, a compound of formula III:



III

5

wherein

[0228] X and Y are independently selected from the group consisting of CH₂, N, C=O, NR⁹, C=S, S=O, SO₂, O, S, (CR⁶R⁷)_n, C(=O)-(CR⁶R⁷)_n, and C(=S)-(CR⁶R⁷)_n;

10

[0229] D is selected from the group consisting of N, and C;

[0230] If X is N, then Y is not N, but may be NH;

[0231] If Y is N, then X is not N, but may be NH;

[0232] If X is CH₂, then Y is not CH₂;

[0233] If Y is CH₂, then X is not CH₂;


15

[0234] If X is NH, then Y is not NH;

[0235] If Y is NH, then X is not NH;

[0236] L is selected from the group consisting of N, O, S, S=O, SO₂, C(O), NC(O), NC(S), OC(O), OC(S), C(NR¹⁰), C(NOR¹⁰), and a covalent bond;

[0237] W is selected from the group consisting of



[0238] Z^1 , Z^2 , and Z^3 are independently selected from the group consisting of CR^8 and N;

[0239] R^1 is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclalkyl, cycloalkylalkyl, alkenyl, alkynyl, and alkyl groups;

[0240] R^2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkylalkyl, aryl, and arylalkyl groups;

[0241] R^3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R^2 and R^3 may join together to form a ring containing at least two N atoms;

[0242] R^4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R^2 and R^4 may join together to form a ring containing at least two N atoms;

[0243] R^5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R^4 and R^5 , together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R^3 and R^5 may join together to form a ring containing at least two N atoms;

[0244] R^6 and R^7 may be the same or different, and are each independently selected from the group consisting of H, Cl, I, F, Br, OH, NH_2 ,

- 5 CN, NO₂, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;
- 10 **[0245]** R⁸ is independently selected from the group consisting of H, Cl, I, F, Br, OH, NH₂, CN, NO₂, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and
- 15 heteroarylaminocarbonyl groups; and
- [0246]** R⁹ and R¹⁰ are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, alkylcarbonyl, and arylcarbonyl groups.
- 20 **[0247]** Compounds provided by the invention further include prodrugs of the compound of formula III, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.
- [0248]** In one embodiment, X is CH₂, Y is C=O, and D is N.
- 25 **[0249]** In another embodiment, X is C=O, Y is CH₂, and D is N.
- [0250]** In another embodiment, X is C=O, Y is C=O, and D is N.
- [0251]** In another embodiment, X is N, Y is NH, D is C, and the bond between X and D is a double bond.
- [0252]** In another embodiment, X is NH, Y is N, D is C, and the bond
- 30 between Y and D is a double bond.

- 5 **[0253]** In another embodiment, X, Y, and D have any of the values of previous embodiments, and L is a covalent bond.
- [0254]** In another embodiment, X, Y, D, and L have any of the values of previous embodiments, and Z¹, Z², and Z³ are all CH.
- [0255]** In another embodiment, X, Y, D, and L have any of the values of previous embodiments, and at least one of Z¹, Z², or Z³ is N.
- 10 **[0256]** In another embodiment, X, Y, D, L, Z¹, Z², and Z³ have any of the values of previous embodiments, and R¹ is selected from the group consisting of substituted and unsubstituted arylalkyl, alkenyl, heteroarylalkyl, and heterocyclylalkyl groups.
- 15 **[0257]** In another embodiment, X, Y, D, L, Z¹, Z², and Z³ have any of the values of previous embodiments, and R¹ is 2,4-disubstituted phenethyl.
- [0258]** In another embodiment, X, Y, D, L, Z¹, Z², and Z³ have any of the values of previous embodiments, and R¹ is selected from the group consisting of 2,4-dihalophenethyl, and 2,4-dialkylphenethyl.
- 20 **[0259]** In another embodiment, X, Y, D, L, Z¹, Z², and Z³ have any of the values of previous embodiments, and R¹ is selected from the group consisting of phenethyl, 2,4-dichlorophenethyl, 4-methoxyphenethyl, 4-bromophenethyl, 4-methylphenethyl, 4-chlorophenethyl, 4-chlorobenzyl, 4-ethylphenethyl, cyclohexenylethyl, 2-methoxyphenethyl, 2-chlorophenethyl, 2-fluorophenethyl,
- 25 3-methoxyphenethyl, 3-fluorophenethyl, thienylethyl, indolylethyl, 4-hydroxyphenethyl, and 3,4-dimethoxyphenethyl.
- [0260]** In another embodiment, X, Y, D, L, Z¹, Z², Z³, and R¹ have any of the values of previous embodiments, and R² is H.
- [0261]** In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl,
- 30

- 5 heteroaryl, heterocyclyl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups.

[0262] In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted cycloalkyl, alkenyl, alkyl, and aryl
10 groups.

[0263] In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-alkylcyclohexyl, 2,2-dialkylcyclohexyl, 2,3-dialkylcyclohexyl, 2,4-dialkylcyclohexyl, 2,5-dialkylcyclohexyl, 2,6-dialkylcyclohexyl, 3,4-dialkylcyclohexyl, 3-alkylcyclohexyl,
15 4-alkylcyclohexyl, 3,3,5-trialkylcyclohexyl, cyclohexylmethyl, 2-aminocyclohexyl, 3-aminocyclohexyl, 4-aminocyclohexyl, 2,3-diaminocyclohexyl, 2,4-diaminocyclohexyl, 3,4-diaminocyclohexyl, 2,5-diaminocyclohexyl, 2,6-diaminocyclohexyl, 2,2-diaminocyclohexyl, 2-alkoxycyclohexyl, 3-alkoxycyclohexyl, 4-alkoxycyclohexyl, 2,3-dialkoxycyclohexyl, 2,4-dialkoxycyclohexyl, 3,4-dialkoxycyclohexyl, 2,5-dialkoxycyclohexyl, 2,6-dialkoxycyclohexyl, 2,2-dialkoxycyclohexyl, 2-alkylthiocyclohexyl, 3-alkylthiocyclohexyl, 4-alkylthiocyclohexyl, 2,3-dialkylthiocyclohexyl, 2,4-dialkylthiocyclohexyl, 3,4-dialkylthiocyclohexyl, 2,5-dialkylthiocyclohexyl, 2,6-dialkylthiocyclohexyl, 2,2-dialkylthiocyclohexyl,
20 cyclopentyl, cycloheptyl, cyclohexenyl, isopropyl, n-butyl, cyclooctyl, 2-aryl cyclohexyl, 2-phenylcyclohexyl, 2-arylalkylcyclohexyl, 2-benzylcyclohexyl, 4-phenylcyclohexyl, adamantyl, isocamphenyl, carenyl, 7,7-dialkylnorbornyl, bornyl, norbornyl, and decalinyl groups.

[0264] In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, and R² have any of the values of previous embodiments, and R³ is selected from the group consisting of substituted and unsubstituted cyclohexyl, 2-methylcyclohexyl, 2,2-dimethylcyclohexyl, 2,3-dimethylcyclohexyl, 2,4-dimethylcyclohexyl, 2,5-dimethylcyclohexyl, 2,6-dimethylcyclohexyl, 3,4-dimethylcyclohexyl, 3-methylcyclohexyl, 4-methylcyclohexyl, cyclohex-3-enyl, 3,3,5-
35 methylcyclohexyl, 4-methylcyclohexyl, cyclohex-3-enyl, 3,3,5-

- 5 trimethylcyclohexyl, 4-*t*-butylcyclohexyl, 2-methylcycloheptyl, cyclohexylmethyl, isopinocampheyl, 7,7-dimethylnorbornyl, 4-isopropylcyclohexyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, and 3-methylcycloheptyl.

[0265] In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁵ is selected from the group
10 consisting of substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups.

[0266] In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, R⁴ is H, and R⁵ is selected from the
15 group consisting of substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.

[0267] In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, R⁴ is H, and R⁵ is selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-
20 ethylbenzyl, 3-chlorobenzyl, 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.

[0268] In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁴ and R⁵ may be the same or different and are each independently selected from the group consisting of
25 substituted and unsubstituted alkyl, arylalkyl, and heteroarylalkyl groups.

[0269] In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁴ and R⁵ may be the same or different and are each independently selected from the group consisting of substituted and unsubstituted dialkylaminoethyl, 4-ethylbenzyl, 3-chlorobenzyl,
30 2,4-dichlorobenzyl, 3-methylbenzyl, benzyl, 4-fluorobenzyl, 3-methoxybenzyl, 2-chlorobenzyl, and thiophene groups.

[0270] In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁴ and R⁵, together with the

- 5 nitrogen to which they are bound, form a substituted or unsubstituted piperazino, morpholino, pyrrolidino, piperidino, homopiperazino, or azepino group.

- [0271] In another embodiment, X, Y, D, L, Z¹, Z², Z³, R¹, R² and R³ have any of the values of previous embodiments, and R⁴ and R⁵, together with the
10 nitrogen to which they are bound, form a piperazino group optionally substituted by one or two alkyl groups, for example, one or two methyl groups.

[0272] There has also been provided, in accordance with another aspect of the invention, a composition comprising a compound according to the instant invention and a pharmaceutically acceptable carrier.

- 15 [0273] There has also been provided, in accordance with another aspect of the invention, a method of activating MC4-R, comprising administering to a subject in need thereof, an effective amount of a compound or composition of the instant invention.


- [0274] There has also been provided, in accordance with another aspect
20 of the invention, a method of treating an MC4-R mediated disease, comprising administering to a subject in need thereof, a compound or composition of the instant invention.

[0275] In one embodiment, a disease to be treated by those methods of the instant invention is obesity, or type I or type II diabetes.

- 25 [0276] There has also been provided, in accordance with another aspect of the invention, a method of decreasing blood glucose levels, comprising administering to a subject in need thereof, a compound or composition of the instant invention.

- [0277] In various alternative embodiments, the composition is
30 administered orally, rectally, by subcutaneous injection, by intravenous injection, by intramuscular injection, or by intraperitoneal injection.

- 5 **[0278]** The variables " $(\text{CR}^6\text{R}^7)_n$ ", " $\text{C}(=\text{O})-(\text{CR}^6\text{R}^7)_n$ ", and " $\text{C}(=\text{S})-(\text{CR}^6\text{R}^7)_n$ " are used with respect to X and Y in compounds of formula I, II, and III where n has the value of 1, 2, or 3. The variable " $(\text{CR}^6\text{R}^7)_n$ " has the same meaning in compounds of formula I, II, and III. The same is true with respect to the variables " $\text{C}(=\text{O})-(\text{CR}^6\text{R}^7)_n$ " and " $\text{C}(=\text{S})-(\text{CR}^6\text{R}^7)_n$ ". Compounds of formula I will be used to illustrate what these variables mean. In compounds of formula I as shown below



I

- X and Y are independently selected from the group consisting of CH_2 , N, NH, $\text{C}=\text{O}$, $\text{C}=\text{S}$, $\text{S}=\text{O}$, SO_2 , O, $(\text{CR}^6\text{R}^7)_n$, $\text{C}(=\text{O})-(\text{CR}^6\text{R}^7)_n$, and $\text{C}(=\text{S})-(\text{CR}^6\text{R}^7)_n$; and n is 1, 2, or 3 as described above. The variable " $(\text{CR}^6\text{R}^7)_n$ " indicates that X and/or Y may be a one, two, or three carbon chain with the carbons bearing the R^6 and R^7 groups. Thus, if X is a three carbon chain ($n = 3$) and Y is a one carbon chain, the ring bearing the X, Y and N will contain 7 members. It should be noted that where $n = 3$ and X or Y is a " $(\text{CR}^6\text{R}^7)_n$ " group, the three carbon chain may be substituted where each carbon bears the same R^6 and R^7 substituents although this is not required. For example, X could be a $-\text{CH}_2\text{CH}(\text{Cl})\text{C}(\text{Cl})_2-$ group because R^6 and R^7 may be H and Cl. Thus, the nomenclature used herein is not meant to restrict each of the carbons to bearing exactly the same substituents as would be the case for $n = 3$ for an X group such as $-\text{CH}(\text{Cl})-\text{CH}(\text{Cl})-\text{CH}(\text{Cl})-$. This same feature is true with respect to the variables " $\text{C}(=\text{O})-(\text{CR}^6\text{R}^7)_n$ " and " $\text{C}(=\text{S})-(\text{CR}^6\text{R}^7)_n$ ". With respect to the variables " $\text{C}(=\text{O})-(\text{CR}^6\text{R}^7)_n$ " and " $\text{C}(=\text{S})-(\text{CR}^6\text{R}^7)_n$ ", X and/or Y may contain from two to four carbon atoms since $n = 1, 2, \text{ or } 3$, and the $\text{C}=\text{O}$ and $\text{C}=\text{S}$ groups of these species contains one carbon atoms. With respect to the variables " $\text{C}(=\text{O})-(\text{CR}^6\text{R}^7)_n$ " and " $\text{C}(=\text{S})-(\text{CR}^6\text{R}^7)_n$ ", either terminus of the group may be bonded to the N atom in the ring containing the X, Y, and N. Thus, the carbonyl carbon of the $\text{C}(=\text{O})-(\text{CR}^6\text{R}^7)_n$ group may be the carbon directly

- 5 bonded to the N in the ring, but one of the CR⁶R⁷ carbons may alternatively be bonded to the ring N atom. Preferably, however, it is the C=O and C=S carbons of such groups that is bonded to the ring N atoms.

[0279] As described above, in some embodiments L may be a covalent bond. In embodiments where L is a covalent bond, the R¹ group is directly
10 bonded to the N in the ring containing the X and Y in compounds of formula I or is directly bonded to A or D in the ring containing the X and Y in compounds of formulas II and III respectively.

[0280] Pharmaceutically acceptable salts include a salt with an inorganic base, organic base, inorganic acid, organic acid, or basic or acidic amino acid.
15 As salts of inorganic bases, the invention includes, for example, alkali metals such as sodium or potassium, alkali earth metals such as calcium and magnesium or aluminum, and ammonia. As salts of organic bases, the invention includes, for example, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine. As salts of inorganic
20 acids, the instant invention includes, for example, hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid. As salts of organic acids, the instant invention includes, for example, formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, and
25 p-toluenesulfonic acid. As salts of basic amino acids, the instant invention includes, for example, arginine, lysine and ornithine. Acidic amino acids include, for example, aspartic acid and glutamic acid.

[0281] Prodrugs, as used in the context of the instant invention, includes those derivatives of the instant compounds which undergo *in vivo* metabolic
30 biotransformation, by enzymatic or nonenzymatic processes, such as hydrolysis, to form a compound of the invention. Prodrugs can be employed to improve pharmaceutical or biological properties, as for example solubility, melting point, stability and related physicochemical properties, absorption, pharmacodynamics and other delivery-related properties.

5 **[0282]** The invention also includes tautomers of the instant compounds. For example, the instant invention also includes all tautomers of formula I, II, and III.

[0283] The instant invention also, therefore, includes prodrugs, pharmaceutically acceptable salts, stereoisomers, hydrates, hydrides, or
10 solvates of these tautomers.

[0284] The instant compounds may exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. In some cases, one stereoisomer may be more active and/or may exhibit beneficial effects in comparison to other stereoisomer(s) or
15 when separated from the other stereoisomer(s). However, it is well within the skill of the ordinary artisan to separate, and/or to selectively prepare said stereoisomers. Accordingly, "stereoisomers" of the instant invention necessarily includes mixtures of stereoisomers, individual stereoisomers, or optically active forms.

20 **[0285]** The instant invention also provides for compositions which may be prepared by mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts or tautomers thereof, with pharmaceutically acceptable carriers, excipients, binders, diluents or the like, to treat or ameliorate a variety of disorders. Examples of such disorders include, but are
25 not limited to obesity, erectile disorders, cardiovascular disorders, neuronal injuries or disorders, inflammation, fever, cognitive disorders, sexual behavior disorders. A therapeutically effective dose further refers to that amount of one or more compounds of the instant invention sufficient to result in amelioration of symptoms of the disorder. The pharmaceutical compositions of the instant
30 invention can be manufactured by methods well known in the art such as conventional granulating, mixing, dissolving, encapsulating, lyophilizing, emulsifying or levigating processes, among others. The compositions can be in the form of, for example, granules, powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions. The
35 instant compositions can be formulated for various routes of administration, for

5 example, by oral administration, by transmucosal administration, by rectal administration, or subcutaneous administration as well as intrathecal, intravenous, intramuscular, intraperitoneal, intranasal, intraocular or intraventricular injection. The compound or compounds of the instant invention can also be administered in a local rather than a systemic fashion, such as injection as a sustained release
10 formulation. The following dosage forms are given by way of example and should not be construed as limiting the instant invention.

[0286] For oral, buccal, and sublingual administration, powders, suspensions, granules, tablets, pills, capsules, gelcaps, and caplets are acceptable as solid dosage forms. These can be prepared, for example, by
15 mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts or tautomers thereof, with at least one additive or excipient such as a starch or other additive. Suitable additives or excipients are sucrose, lactose, cellulose sugar, mannitol, maltitol, dextran, sorbitol, starch, agar, alginates, chitins, chitosans, pectins, tragacanth gum, gum arabic, gelatins,
20 collagens, casein, albumin, synthetic or semi-synthetic polymers or glycerides, methyl cellulose, hydroxypropylmethyl-cellulose, and/or polyvinylpyrrolidone. Optionally, oral dosage forms can contain other ingredients to aid in administration, such as an inactive diluent, or lubricants such as magnesium stearate, or preservatives such as paraben or sorbic acid, or anti-oxidants such
25 as ascorbic acid, tocopherol or cysteine, a disintegrating agent, binders, a thickeners, buffers, a sweeteners, flavoring agents or perfuming agents. Additionally, dyestuffs or pigments may be added for identification. Tablets and pills may be further treated with suitable coating materials known in the art.

[0287] Liquid dosage forms for oral administration may be in the form of
30 pharmaceutically acceptable emulsions, syrups, elixirs, suspensions, slurries and solutions, which may contain an inactive diluent, such as water. Pharmaceutical formulations may be prepared as liquid suspensions or solutions using a sterile liquid, such as, but not limited to, an oil, water, an alcohol, and combinations of these. Pharmaceutically suitable surfactants, suspending
35 agents, emulsifying agents, may be added for oral or parenteral administration.

5 **[0288]** As noted above, suspensions may include oils. Such oils include, but are not limited to, peanut oil, sesame oil, cottonseed oil, corn oil and olive oil. Suspension preparation may also contain esters of fatty acids such as ethyl oleate, isopropyl myristate, fatty acid glycerides and acetylated fatty acid glycerides. Suspension formulations may include alcohols, such as, but not
10 limited to, ethanol, isopropyl alcohol, hexadecyl alcohol, glycerol and propylene glycol. Ethers, such as but not limited to, poly(ethyleneglycol), petroleum hydrocarbons such as mineral oil and petrolatum; and water may also be used in suspension formulations.

15 **[0289]** For nasal administration, the pharmaceutical formulations may be a spray or aerosol containing and appropriate solvents and optionally other compounds such as, but not limited to, stabilizers, antimicrobial agents, antioxidants, pH modifiers, surfactants, bioavailability modifiers and combinations of these. A propellant for an aerosol formulation may include
20 compressed air, nitrogen, carbon dioxide, or a hydrocarbon based low boiling solvent. The compound or compounds of the instant invention are conveniently delivered in the form of an aerosol spray presentation from a nebulizer or the like.

25 **[0290]** Injectable dosage forms generally include aqueous suspensions or oil suspensions which may be prepared using a suitable dispersant or wetting agent and a suspending agent. Injectable forms may be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent. Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution. Alternatively, sterile oils may be employed as solvents or suspending agents. Preferably, the oil or fatty acid
30 is non-volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri-glycerides.

35 **[0291]** For injection, the pharmaceutical formulation may be a powder suitable for reconstitution with an appropriate solution as described above. Examples of these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or

- 5 particulates. For injection, the formulations may optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these. The compounds may be formulated for parenteral administration by injection such as by bolus injection or continuous infusion. A unit dosage form for injection may be in ampoules or in multi-dose containers.
- 10 **[0292]** For rectal administration, the pharmaceutical formulations may be in the form of a suppository, an ointment, an enema, a tablet or a cream for release of compound in the intestines, sigmoid flexure and/or rectum. Rectal suppositories are prepared by mixing one or more compounds of the instant invention, or pharmaceutically acceptable salts or tautomers of the compound,
- 15 with acceptable vehicles, for example, cocoa butter or polyethylene glycol, which is present in a solid phase at normal storing temperatures, and present in a liquid phase at those temperatures suitable to release a drug inside the body, such as in the rectum. Oils may also be employed in the preparation of formulations of the soft gelatin type and suppositories. Water, saline, aqueous dextrose and
- 20 related sugar solutions, and glycerols may be employed in the preparation of suspension formulations which may also contain suspending agents such as pectins, carbomers, methyl cellulose, hydroxypropyl cellulose or carboxymethyl cellulose, as well as buffers and preservatives.
- [0293]** Besides those representative dosage forms described above,
- 25 pharmaceutically acceptable excipients and carriers are generally known to those skilled in the art and are thus included in the instant invention. Such excipients and carriers are described, for example, in "Remingtons Pharmaceutical Sciences" Mack Pub. Co., New Jersey (1991), which is incorporated herein by reference.
- 30 **[0294]** The formulations of the invention may be designed for to be short-acting, fast-releasing, long-acting, and sustained-releasing as described below. Thus, the pharmaceutical formulations may also be formulated for controlled release or for slow release.

5 **[0295]** The instant compositions may also comprise, for example, micelles or liposomes, or some other encapsulated form, or may be administered in an extended release form to provide a prolonged storage and/or delivery effect. Therefore, the pharmaceutical formulations may be compressed into pellets or cylinders and implanted intramuscularly or
10 subcutaneously as depot injections or as implants such as stents. Such implants may employ known inert materials such as silicones and biodegradable polymers.

[0296] A therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms. Specific dosages may be
15 adjusted depending on conditions of disease, the age, body weight, general health conditions, sex, diet of the subject, dose intervals, administration routes, excretion rate, and combinations of drugs. Any of the above dosage forms containing effective amounts are well within the bounds of routine experimentation and therefore, well within the scope of the instant invention. A
20 therapeutically effective dose may vary depending upon the route of administration and dosage form. The preferred compound or compounds of the instant invention is a formulation that exhibits a high therapeutic index. The therapeutic index is the dose ratio between toxic and therapeutic effects which can be expressed as the ratio between LD_{50} and ED_{50} . The LD_{50} is the dose
25 lethal to 50% of the population and the ED_{50} is the dose therapeutically effective in 50% of the population. The LD_{50} and ED_{50} are determined by standard pharmaceutical procedures in animal cell cultures or experimental animals.

[0297] The present invention also provides methods of enhancing MC4-R
30 activity in a human or non-human animal. The method comprises administering an effective amount of a compound, or composition, of the instant invention to said mammal or non-human animal. Effective amounts of the compounds of the instant invention include those amounts that activate MC4-R which are detectable, for example, by an assay described below in the illustrative Examples,
35 or any other assay known by those skilled in the art that a detect signal transduction, in a biochemical pathway, through activation of G-protein coupled

5 receptors, for example, by measuring an elevated cAMP level as compared to a control model. Accordingly, "activating" means the ability of a compound to initiate a detectable signal. Effective amounts may also include those amounts which alleviate symptoms of a MC4-R disorder treatable by activating MC4-R.

[0298] An MC4-R disorder, or MC4-R-mediated disease, which may be
10 treated by those methods provided, include any biological disorder or disease in which MC4-R is implicated, or which inhibition of MC4-R potentiates a biochemical pathway that is defective in the disorder or disease state. Examples of such diseases are obesity, erectile disorders, cardiovascular disorders, neuronal injuries or disorders, inflammation, fever, cognitive disorders, and
15 sexual behavior disorders. In a preferred embodiment, the instant invention provides compounds, compositions, and methods effective for reducing energy intake and body weight; reducing serum insulin and glucose levels; alleviating insulin resistance; and reducing serum levels of free fatty acids. Accordingly, the instant invention is particularly effective in treating those disorders or
20 diseases associated with obesity or type II diabetes.

[0299] "Treating" within the context of the instant invention, therefore, means an alleviation of symptoms associated with a disorder or disease, or halt of further progression or worsening of those symptoms, or prevention or prophylaxis of the disease or disorder. For example, within the context of obesity, successful
25 treatment may include an alleviation of symptoms or halting the progression of the disease, as measured by reduction in body weight, or a reduction in amount of food or energy intake. In this same vein, successful treatment of type I or type II diabetes may include an alleviation of symptoms or halting the progression of the disease, as measured by a decrease in serum glucose or insulin levels in, for
30 example, hyperinsulinemic or hyperglycemic patients.


Compound Preparation

[0300] Many of the described specific synthetic transformation steps are familiar to those skilled in the art and their procedures are either described or referenced in common texts such as in March Advanced Organic Chemistry 3rd

5 ed. (Wiley, 1985), Carey and Sundberg Advanced Organic Chemistry A and B
3rd ed. (Plenum Press, 1990), and Vogel's Textbook of Practical Organic
Chemistry 5th ed. (Longman, 1989). Implicit in the synthetic transformations
are various techniques for purification such as silica gel chromatography,
crystallizations, and distillations. These steps may be necessary for isolating
10 the desired product, regioisomer, enantiomer, or diastereomer from a reaction
product mixture. Multistep syntheses may also involve the use of protecting
groups to address issues of chemo and regioselectivity that cannot otherwise
be satisfactorily resolved with respect to chemical purity or yield.

[0301] The use of protecting groups in organic synthesis is well known
15 with respect to various groups such as hydroxyl groups, amine groups, and
sulfhydryl groups. These and other functionalities may be protected from
undesirable reactions with various protecting groups known to those skilled in
the art such as those set forth in Protective Groups in Organic Synthesis,
Greene, T.W., John Wiley & Sons, New York, NY, (1st Edition, 1981) which can
20 be added or removed using the procedures set forth therein. Examples of
protected hydroxyl groups include, but are not limited to, silyl ethers such as
those obtained by reaction of a hydroxyl group with a reagent such as, but not
limited to, t-butyldimethyl-chlorosilane, trimethylchlorosilane,
triisopropylchlorosilane, triethylchlorosilane; substituted methyl and ethyl ethers
25 such as, but not limited to methoxymethyl ether, methylthiomethyl ether,
benzyloxymethyl ether, t-butoxymethyl ether, 2-methoxyethoxymethyl ether,
tetrahydropyranyl ethers, 1-ethoxyethyl ether, allyl ether, benzyl ether; esters
such as, but not limited to, benzoylformate, formate, acetate, trichloroacetate,
and trifluoroacetate. Examples of protected amine groups include, but are not
30 limited to, amides such as, formamide, acetamide, trifluoroacetamide, and
benzamide; imides, such as phthalimide, and dithiosuccinimide; and others.
Examples of protected sulfhydryl groups include, but are not limited to,
thioethers such as S-benzyl thioether, and S-4-picolyl thioether; substituted S-
methyl derivatives such as hemithio, dithio and aminothio acetals; and others.

- 5 [0302] Figure 1 illustrates a general synthetic route for compounds containing the following core structure:




- [0303] In the first part of the synthesis the non-guanidino linked portion of the bicyclic core is functionalized. In one embodiment of the method of the invention, the condensation of an amine and an anhydride gives an N-substituted phthalimide. Alternatively, if a phthalimide is used as the starting material, the phthalimide nitrogen may be functionalized by displacement of an activated alcohol. These transformations allow access to a wide range of N-substituted intermediates by varying the type of R₁OH or R₁NH₂ inputs. It can further be appreciated that use of the appropriate starting materials for the bicyclic core can also provide, for example, compounds of the invention containing a nitrogen atom in the aromatic ring to which the guanidino moiety is attached.

- [0304] In the next phase of the synthetic route, the functionalized imide may be reduced to the lactam via a two step process. After separation of the desired lactam regioisomer, the primary amine may be activated by treatment with thiophosgene to form the thioisocyanate. Sequential coupling of two amines yields the desired lactam products, which can exist in two tautomeric forms. One skilled in the art would recognize that alternative couplings of amines to thioureas exist, such as the use of a myriad of carbodiimide based coupling reagents or alkylation of the sulfur atom with an alkyl halide prior to addition of an amine.

5


Figure 1



[0305] Use of the other regioisomer obtained from the reduction step would lead to the regioisomeric lactam and its tautomer shown in Figure 2

10 below.

Figure 2




[0306] Furthermore, the reduction steps in Figure 1 can be omitted in its entirety and the reaction scheme can be carried through to give the guanidino imide and its tautomer shown in Figure 3 as products. Conversely, both

15 carbonyl groups can be fully reduced to give the tetrahydro analogs.


5

Figure 3



- [0307] Additional structural variations within the non-guanidino linked portion of the bicyclic core itself can be achieved by starting with, for example, bicyclic lactams or bicyclic cyloamido compounds. These scaffolds can be generally be functionalized by methods known in the art such as N-alkylation with a variety of electrophiles (see R. Larock, Comprehensive Organic Transformations; VHC Publisher's Inc., 1989). Bicyclic lactams can also be generally functionalized as shown in Figure 4. An amine or its activated equivalent (for example an alkyl aluminum amide) is first coupled with a lactone. The resulting product is then used in a subsequent cyclodehydration reaction (for example a Mitsunobu reaction) to give the functionalized bicyclic core. The guanidino moiety may then be installed as described above.


Figure 4



- 20 [0308] Figure 5 illustrates a general synthetic route for compounds of the invention containing the benzimidazole core structure. An activated acid is first


- 5 condensed with a diaminonitrophenyl starting material followed by exposure of the resulting product to acidic conditions to provide the benzimidazole core. The nitro moiety is then reduced and converted to the functionalized guanidino substituent as described above.

Figure 5



- [0309] In another embodiment of the invention, benzoxazole and benzthiazole comprise the bicyclic core. These compounds may be constructed as shown in Figure 6. Commercially available (Aldrich) 6-nitrobenzothiazole may be treated with base and quenched with N-chlorosuccinimide to give the halogenated intermediate. This compound may then be used in a number of metal mediated coupling reactions (for example Heck, Stille, Sonogashira coupling reactions) to functionalize the bicyclic core. The nitro group then serves as the attachment point for the guanidino unit.
- 15

Figure 6



- [0310] The present invention, thus generally described, will be understood more readily by reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention.

5

EXAMPLES

[0311] Compounds were named using the ACD/Name v. 4.53.

[0312] The following abbreviations are used throughout the Examples:

	eq	equivalent
	DIAD	diisopropylazodicarboxylate
10	DIBAL-H	diisobutylaluminum hydride
	EDC	1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide hydrochloride
	EtOAc	ethylacetate
	THF	tetrahydrofuran
	TFA	trifluoroacetic acid

15

Analytical Methodology

[0313] **HPLC System:** HPLC was run on a Waters 2690 HPLC system.

column = Reliasil 50 x 4.6mm (5µm pore size)

method: (note: all solvents include 0.1% TFA)

	time (minutes)	flow rate (mL/min)	%water	%CAN
20	init.	2	95	5
	15	2	20	80
	15.5	2	0	100
	17.5	2	0	100
25	18.5	2	95	5

Model HPLC = (Waters 2690 Separations Module)

detector = (Waters 996 photodiode array detector)

LCMS were run on HP Series 1100 LCMS system

HP LCMS (1100 series)

30 HP MSD (1100 series)

5	time (minutes)	flow rate (mL/min)	%A*	%B*
	0	0.8	95	5
	.2	0.8	95	5
	3.7	0.8	5	95
10	3.85	0.8	95	5
	5	0.8	95	5

*solvent A = (water + 0.05% TFA) and solvent B = (Acetonitrile + 0.05% TFA)
column temp = 30° C

column = (brand = Eclipse XDB) 50 x 2mm (5µm) (C18)

15 **MS Methodology**

MWT: 150-800

CV: 20

Ionization: ESP+

i. Data: Centroid

20 Repeat: 1
Scan Time: 2 seconds

Example 1

[0314] Preparation of (3S)-N-(2-[2-(2,4-dichlorophenyl)ethyl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl)-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

25

Step 1. Preparation of 2-[2-(2,4-dichlorophenyl)ethyl]-5-nitro-1H-isoindole-1,3(2H)-dione

[0315] 2-(2,4-dichlorophenyl)ethanamine was suspended in toluene with 4-nitrophthalic anhydride (1 eq) and heated to 150°C. After 2 hours, the

30 reaction was cooled and checked for completion by LC/MS. The solvent was then removed *in vacuo* and the resulting product was taken on to the next step without further purification. R_t 3.36 minutes (HP LCMS), LC/MS m/z 365.1 (MH+).

5 **Step 2. Preparation of 5-amino-2-[2-(2,4-dichlorophenyl)ethyl]-1H-isoindole-1,3(2H)-dione**

10 **[0316]** The product of the previous step was taken up in ethanol (or methanol) and purged with dry nitrogen. To this solution was introduced activated Pd/C (10% w/w, 0.1 eq) and the mixture was hydrogenated for about 30 minutes or until complete by LC/MS. The mixture was then filtered through celite, concentrated *in vacuo*, and taken on to the next step. R_t 2.95 minutes (HP LCMS), LC/MS m/z 335.0 (MH+).

Step 3. Preparation of 5-amino-2-[2-(2,4-dichlorophenyl)ethyl]-3-hydroxyisoindolin-1-one

15 **[0317]** To a CH_2Cl_2 solution of the phthalimide was added dropwise DIBAL-H (3 eq, 1.0 M solution in CH_2Cl_2) at room temperature with good stirring. After stirring for one hour, the reaction was diluted with ether, NaF (12 eq), and distilled water (9 eq) and stirred for an additional hour. The reaction mixture was then filtered through celite to remove the aluminum precipitants.
20 After washing the celite with additional CH_2Cl_2 , the filtrate was then concentrated *in vacuo* to give a crude product (mixture of regioisomers) was then used in the following step without further purification. R_t 2.09 minutes (HP LCMS) and 2.23 minutes (HP LCMS), LC/MS m/z 337.2 (MH+).

25 **Step 4. Preparation of 5-amino-2-[2-(2,4-dichlorophenyl)ethyl]isoindolin-1-one**

30 **[0318]** To a CH_2Cl_2 (0.1 M solution) of the crude product from the previous step was added dropwise trifluoroacetic acid (6.0 eq) followed immediately by dropwise addition of triethylsilane (2.9 eq). After stirring for an additional 15 minutes, the mixture was concentrated *in vacuo*. The crude product of two regioisomeric lactams was then dissolved in acetonitrile and purified *via* reverse phase (C18) prep HPLC. The fractions for the desired regioisomeric lactam product (later retention time) were collected, frozen, and lyophilized. R_t 7.24minutes, LC/MS m/z 321.1 (MH+).

5 **Step 5. Preparation of 2-[2-(2,4-dichlorophenyl)ethyl]-5-isothiocyanato-isoindolin-1-one**

[0319] To a 0.5 M solution of the amine in acetone (0°C ice bath) was added thiophosgene (3 eq) dropwise. After 30 minutes, the reaction mixture was allowed to warm to room temperature. After two hours, the reaction
10 mixture was concentrated *in vacuo* to remove solvent and excess thiophosgene. The crude isothiocyanate product was then used in the next step without further purification. R_t 3.43 minutes (HP LCMS), LC/MS m/z 363.1 (MH+).

15 **Step 6. Preparation of N-{2-[2-(2,4-dichlorophenyl)ethyl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]thiourea**

[0320] To a solution of the crude isothiocyanate in dry acetonitrile (0.5 M solution) was added (+)-isopinocampheyl amine (1.5 eq). After stirring overnight, the reaction mixture was concentrated *in vacuo* and the thiourea
20 product was dissolved in CH_2Cl_2 and purified *via* flash chromatography (1:1 Hexanes:EtOAc). Fractions containing the thiourea product were concentrated *in vacuo* and dried to yield a creamish white colored solid. R_t 14.53 minutes, LC/MS m/z 516.4 (MH+).

25 **Step 7. Preparation of (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide**

[0321] To a solution of the thiourea in THF (dry, 0.5 M) in a dry vial was added (S)-(+)-2-methylpiperazine (3 eq) and EDC (3 eq). The vial was capped
30 tightly and heated to 80°C for approximately 2 hours. The mixture was then allowed to cool to room temperature and concentrated *in vacuo*. The reaction mixture was dissolved in DMSO along with TFA (1 eq) and purified by prep

- 5 HPLC. The pure fractions were collected, frozen, and dried *via* lyophilization to give the product as a white solid. R_t 8.36 minutes, LC/MS m/z 582.5 (MH+).

Example 2

- [0322] Preparation of (3S)-N-[2-[2-(2,4-dichlorophenyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide
- 10

Step 1. Preparation of 2-[2-(2,4-dichlorophenyl)ethyl]-5-nitro-1H-isoindole-1,3(2H)-dione

- [0323] 2-(2,4-dichlorophenyl)ethanamine was suspended in toluene with 4-nitrophthalic anhydride (1 eq) and heated to 150°C. After 2 hours, the
- 15 reaction was cooled and checked for completion by LC/MS. The solvent was then removed *in vacuo* and the resulting product was taken on to the next step without further purification. R_t 3.91 minutes, LC/MS m/z 365.1 (MH+).

Step 2. Preparation of 5-amino-2-[2-(2,4-dichlorophenyl)ethyl]-1H-isoindole-1,3(2H)-dione

- [0324] The product of the previous step was taken up in ethanol (or methanol) and purged with dry nitrogen. To this solution was introduced activated Pd/C (10% w/w, 0.1 eq) and the mixture was hydrogenated for about 30 minutes or until complete by LC/MS. The mixture was then filtered through celite, concentrated *in vacuo*, and taken on to the next step. R_t 2.96 minutes
- 25 (HP LCMS), LC/MS m/z 335.1 (MH+).

Step 3. Preparation of 2-[2-(2,4-dichlorophenyl)ethyl]-5-isothiocyantoiso-1H-isoindole-1,3(2H)dione

- [0325] To a 0.5 M solution of the amine in acetone (0°C ice bath) was added thiophosgene (3 eq) dropwise. After 30 minutes, the reaction mixture
- 30 was allowed to warm to room temperature. After two hours, the reaction mixture was concentrated *in vacuo* to remove solvent and excess

5 thiophosgene. The crude isothiocyanate product was then used in the next step without further purification. R_t 3.75 minutes (HP LCMS), LC/MS m/z 377.0 (MH+).

10 **Step 4. Preparation of N-{2-[2-(2,4-dichlorophenyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]thiourea**

[0326] To a solution of the crude isothiocyanate in dry acetonitrile (0.5 M solution) was added (+)-isopinocampheyl amine (1.5 eq). After stirring overnight, the reaction mixture was concentrated *in vacuo* and the thiourea product was dissolved in CH_2Cl_2 and purified *via* flash chromatography (1:1
15 Hexanes:EtOAc). Fractions containing the thiourea product were concentrated *in vacuo* and dried overnight *via* lyophilization to yield a yellowish-brown solid. R_t 3.98 minutes (HP LCMS), LC/MS m/z 596.1 (MH+).

20 **Step 5. Preparation of (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl]-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide**

[0327] To a solution of the thiourea in THF (dry, 0.5 M) in a dry vial was added (S)-(+)-2-methylpiperazine (3 eq) and EDC (3 eq). The vial was capped tightly and heated to 80°C for approximately 2 hours. The mixture was then
25 allowed to cool to room temperature and concentrated *in vacuo*. The reaction mixture was dissolved in DMSO along with TFA (1 eq) and purified by prep HPLC. The pure fractions were collected, frozen, and dried *via* lyophilization to give the product as a white solid. R_t 9.57 minutes, LC/MS m/z 596.3 (MH+).

[0328] Examples 3-16 were prepared using the procedures described for
30 1 and 2.

5

Example 3

[0329] (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-3-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

[0330] Synthesized from 2-(2,4-dichlorophenyl)ethanamine. R_t 8.72 minutes, LC/MS m/z 582.5 (MH+).

Example 4

[0331] (3S)-N-[2-(2,4-dichlorobenzyl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

[0332] Synthesized from 1-(2,4-dichlorophenyl)methanamine. R_t 8.72 minutes, LC/MS m/z 582.5 (MH+).

Example 5

[0333] (3S)-N-{2-[(1S)-1-benzyl-2-hydroxyethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

[0334] Synthesized from L-phenylalaninol. R_t 7.56 minutes, LC/MS m/z 558.7 (MH+).

Example 6

[0335] (3S)-N-{2-[(1R)-1-benzyl-2-hydroxyethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

[0336] Synthesized from D-phenylalaninol. R_t 7.52 minutes, LC/MS m/z 558.7 (MH+).

5

Example 7

[0337] (3S)-N-{2-[2-(2-fluoro-4-methylphenyl)ethyl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

[0338] Synthesized from 2-(3-fluoro-5-methylphenyl)ethanamine. R_t 7.8 minutes, LC/MS m/z 546.2 (MH+).

10

Example 8

[0339] (3S)-N-{2-[(1S)-1-(2,4-dichlorobenzyl)-2-hydroxyethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

[0340] Synthesized from L-2,4-dichlorophenylalaninol, obtained in one step from the reduction of L-2,4-dichlorophenylalanine (see, for example, *JOC* 2000, 65, 5037-5042). R_t 8.46 minutes, LC/MS m/z 626.2 (MH+).

15

Example 9

[0341] (3S)-N-{2-[(1S)-1-(2,4-dichlorobenzyl)-2-hydroxyethyl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

20

[0342] Synthesized from L-2,4-dichlorophenylalaninol, obtained in one step from the reduction of L-2,4-dichlorophenylalanine (see, for example, *JOC* 2000, 65, 5037-5042). R_t 7.71 minutes, LC/MS m/z 612.2 (MH+).

25

Example 10

[0343] (3S)-N-{2-[2-(2-fluoro-4-methoxyphenyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

- 5 **[0344]** Synthesized from 2-(2-fluoro-4-methoxyphenyl)ethanamine. R_t 8.4 minutes, LC/MS m/z 576.2 (MH⁺).

Example 11

- [0345]** (3S)-N-{2-[2-(2,4-difluorophenyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide
10

[0346] Synthesized from 2-(2,4-difluorophenyl)ethanamine. R_t 8.53 minutes, LC/MS m/z 564.2 (MH⁺).

Example 12

- [0347]** (3S)-N-{2-[2-(2,4-dimethoxyphenyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide
15

[0348] Synthesized from 2-(2,4-dimethoxyphenyl)ethanamine. R_t 8.51 minutes, LC/MS m/z 588.3 (MH⁺).

Example 13

- 20 **[0349]** (3S)-N-{2-[2-(2,4-dimethylphenyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

[0350] Synthesized from 2-(2,4-dimethylphenyl)ethanamine. R_t 9.43 minutes, LC/MS m/z 556.2 (MH⁺).

25

Example 14

- [0351]** (3S)-N-{2-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

- 5 **[0352]** Synthesized from (1S,2S)-(+)-2-amino-1-phenyl-1,3-propanediol. R_t 6.68 minutes, LC/MS m/z 574.3 (MH+).

Example 15

- 10 **[0353]** (3S)-N-{2-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

[0354] Synthesized from (1R,2R)-(-)-2-amino-1-phenyl-1,3-propanediol. R_t 6.64 minutes, LC/MS m/z 574.3 (MH+).

Example 16

- 15 **[0355]** (3S)-N-{2-[(1S,2R)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

[0356] Synthesized from (1R,2S)-(+)-2-amino-1-phenyl-1,3-propanediol. R_t 6.63 minutes, LC/MS m/z 574.3 (MH+).

Example 17

- 20 **[0357]** (3S)-N-{2-[2-(2-fluoro-4-methoxyphenyl)ethyl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

[0358] Synthesized from 2-(2-fluoro-4-methoxyphenyl)ethanamine. R_t 7.42 minutes, LC/MS m/z 562 (MH+).

25

Example 18

- [0359]** (3S)-N-{2-[2-(2,4-difluorophenyl)ethyl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

[0360] Synthesized from 2-(2,4-difluorophenyl)ethanamine. R_t 7.5 minutes, LC/MS m/z 550 (MH+).

Example 19

[0361] (3S)-N-{2-[2-(2,4-difluorophenyl)ethyl]-3-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

[0362] Synthesized from 2-(2,4-difluorophenyl)ethanamine. R_t 7.82 minutes, LC/MS m/z 550 (MH+).

Example 20

[0363] (3S)-N-{2-[2-(2,4-dimethylphenyl)ethyl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

[0364] Synthesized from 2-(2,4-dimethylphenyl)ethanamine. R_t 8.21 minutes, LC/MS m/z 542.1 (MH+).

Example 21

[0365] (3S)-N-{2-[2-(2,4-dimethylphenyl)ethyl]-3-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

[0366] Synthesized from 2-(2,4-dimethylphenyl)ethanamine. R_t 8.5 minutes, LC/MS m/z 542.1 (MH+).

Example 22

[0367] (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl}-3-methyl-N'-[(1S,2S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide

- 5 **[0368]** 6-nitroisochroman-1-one was treated with the dimethylaluminum amide prepared from 2-(2,4-dichlorophenyl)ethanamine, and the product obtained was cyclized using Mitsunobu conditions (as in Ian. Bell et al, Tetrahedron. Lett. (2000),41, 1141-1145). The nitro group was then reduced, and the amine was converted to the substituted guanidine (as in steps 2-5 of
- 10 Example 2 above) to give the title compound. R_t 9.06 minutes, LC/MS m/z 596.1 (MH+).

Example 23

- [0369]** (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1H-benzimidazol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-
- 15 carboximidamide
- [0370]** 2,4-dichlorophenyl propionic acid (1.0 eq) was mixed with 4-nitro-1,2-phenylenediamine (1.1 eq) and EDC (1.5 eq) in THF at room temperature for 8 hours. The solution was diluted with ethyl acetate and washed with water (3 x). The combined organic layers were dried over sodium sulfate, filtered, and
- 20 concentrated *in vacuo*. The product was then subjected to refluxing glacial acetic acid for 30 minutes. After removal of the acetic acid *in vacuo*, the residue was free-based with sodium carbonate. The resulting compound was then subjected to the hydrogenation and guanidino functionalization conditions described in Example 2 above (steps 2, 3, 4, and 5) to give the desired product.
- 25 R_t 7.08 minutes, LC/MS m/z 567.2 (MH+).

[0371] Examples 24 and 25 can be prepared using the procedures described for Example 23.

Example 24

- [0372]** (3S)-N-{2-[2-(2,4-dimethylphenyl)ethyl]-1H-benzimidazol-6-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-
- 30 carboximidamide

- 5 **[0373]** Synthesized from 3-(2,4-dimethylphenyl)propanoic acid. R_t 6.93 minutes, LC/MS m/z 527.3 (MH⁺).

Example 25

- [0374]** (3S)-N-{2-[2-(2-chloro-4-fluorophenyl)ethyl]-1H-benzimidazol-6-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide
10

[0375] Synthesized from 3-(2-chloro-4-fluorophenyl)propanoic acid. R_t 6.54 minutes, LC/MS m/z 551.4 (MH⁺).

- [0376]** In addition to the synthesis described above, many of the synthetic transformations presented in U.S. Provisional Application No. 60/245,579 are relevant to the synthesis of the compounds of the present invention. Thus, U.S. Provisional Application No. 60/245,579, filed November 6, 2000 is hereby incorporated by reference in its entirety.
15

In Vitro Data

- [0377]** EC₅₀ values of test compounds were determined by treating cells expressing MC4-R with test compound and lysing the cells and measuring intercellular cAMP concentration with an Amersham-Pharmacia RPA-559 cAMP Scintillation Proximity Assay (SPA) kit. The following compounds were synthesized and tested according to this assay. The following compounds are merely illustrative and should not be construed as limiting of the instant invention. Compounds having an *in vitro* potency (as measured by EC₅₀ value) of less than 3 μ M include:
20
25

- [0378]** (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide; (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide; (3S)-N-{2-[2-
30

- 5 (2,4-dichlorophenyl)ethyl]-3-oxo-2,3-dihydro-1H-isoindol-5-yl]-3-methyl-N'-
[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-
carboximidamide; (3S)-N-[2-(2,4-dichlorobenzyl)-1,3-dioxo-2,3-dihydro-1H-
isoindol-5-yl]-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-
yl]piperazine-1-carboximidamide; (3S)-N-[2-[(1S)-1-benzyl-2-hydroxyethyl]-1,3-
10 dioxo-2,3-dihydro-1H-isoindol-5-yl]-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-
trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide; (3S)-N-[2-[(1R)-
1-benzyl-2-hydroxyethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]-3-methyl-N'-
[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-
carboximidamide; (3S)-N-[2-[2-(2-fluoro-4-methylphenyl)ethyl]-1-oxo-2,3-
15 dihydro-1H-isoindol-5-yl]-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-
trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide; (3S)-N-[2-[(1S)-
1-(2,4-dichlorobenzyl)-2-hydroxyethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]-
3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-
carboximidamide; (3S)-N-[2-[2-(2-fluoro-4-methoxyphenyl)ethyl]-1,3-dioxo-2,3-
20 dihydro-1H-isoindol-5-yl]-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-
trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide; (3S)-N-[2-[2-
(2,4-difluorophenyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]-3-methyl-N'-
[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-
carboximidamide; (3S)-N-[2-[2-(2,4-dimethoxyphenyl)ethyl]-1,3-dioxo-2,3-
25 dihydro-1H-isoindol-5-yl]-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-
trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide; (3S)-N-[2-[2-
(2,4-dimethylphenyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]-3-methyl-N'-
[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-
carboximidamide; (3S)-N-[2-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-
30 phenylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]-3-methyl-N'-
[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-
carboximidamide; (3S)-N-[2-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-
phenylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]-3-methyl-N'-
[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-
35 carboximidamide; (3S)-N-[2-[(1S,2R)-2-hydroxy-1-(hydroxymethyl)-2-
phenylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]-3-methyl-N'-

- 5 [(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide; (3S)-N-{2-[2-(2-fluoro-4-methoxyphenyl)ethyl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide; (3S)-N-{2-[2-(2,4-difluorophenyl)ethyl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-
- 10 [(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide; (3S)-N-{2-[2-(2,4-difluorophenyl)ethyl]-3-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide; (3S)-N-{2-[2-(2,4-dimethylphenyl)ethyl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-
- 15 trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide; (3S)-N-{2-[2-(2,4-dimethylphenyl)ethyl]-3-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide; (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1H-benzimidazol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-
- 20 1-carboximidamide; (3S)-N-{2-[2-(2,4-dimethylphenyl)ethyl]-1H-benzimidazol-6-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide; (3S)-N-{2-[2-(2,4-dichlorophenyl)ethyl]-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl}-3-methyl-N'-[(1S,2S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide; (3S)-N-{2-[(1S)-
- 25 1-(2,4-dichlorobenzyl)-2-hydroxyethyl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-1-piperazinecarboximidamide; and (3S)-N-{2-[2-(2-chloro-4-fluorophenyl)ethyl]-1H-benzimidazol-6-yl}-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide.

30 **In Vivo Studies of MC4-R Agonists on Energy Intake, Body Weight, Hyperinsulinemia, and Glucose Levels.**

- [0379] In vivo studies are conducted to observe the effect of MCR-4 agonists on energy intake, body weight, hyperinsulinemia, and glucose levels. All studies are conducted with male 9-10 week old ob/ob mice which display
- 35 early onset of obesity, insulin resistance and diabetes due to leptin deficiency.

lice are acclimated in the facility for 1 week before studies and are caged individually. Vehicle-treated (control) and drug treated mice studies are always run in parallel. In multi-day studies, mice (8-15 per group) are monitored for baseline body weight, fasting levels of glucose, insulin, blood lipids and energy expenditure and then are injected twice daily (9 a.m. and 5 p.m.) with 3mg/kg of an MC4-R agonist according to the invention for 2-4 weeks. Body weight as well as food and water intake are monitored daily. Animals are fasted overnight for measurements of fasting levels of glucose, insulin, and lipids once a week until the end of the study. Energy expenditure (resting metabolic rate, i.e., O₂ consumption and CO₂ production) are monitored in air tight chambers at the end of the study on fed animals. O₂ consumption and CO₂ production are measured using Oxymax systems (Columbus Instruments). Oral glucose tolerance test (OGTT – a routine test for diabetes and glucose intolerance) is performed on overnight fasted mice at the end of the study. Blood glucose and oral glucose tolerance are measured using a glucose monitor (Onetouch sold by Lifescan). Free fatty acids are measured using a nonesterified free fatty acids enzymatic assay (Waco Chemicals). Serum Insulin levels are measured by immunoassay (Alpco).

[0380] The results of the above studies show that a significant reduction in food intake occurs in those mice treated IP with the compounds of the present invention. The results also show that mice treated with the compounds of the present invention show a significant body weight reduction compared to mice not treated with the compounds of the present invention. Vehicle treated mice show an increase in blood glucose consistent with the rapid progression of diabetes in this mouse strain, whereas the onset of diabetes is slowed down in mice treated with the compounds of the present invention. Oral glucose tolerance tests are performed. Orally administered glucose quickly elevates blood glucose similar to after eating a meal. Vehicle treated mice show an elevated response to glucose consistent with their diabetic state, whereas mice treated with the compounds of the present invention show a very much [REDACTED] glucose disposal. Mice are fasted overnight and free fatty acid levels

- 5 are measured the following morning. Vehicle treated mice show elevated free fatty acid levels consistent with their obese state, whereas mice treated with the compounds of the present invention show a dramatic 50% decrease. Serum insulin levels are measured one hour after single IP dosing of compounds of the present invention in overnight fasted ob/ob mice. Mice treated with the
- 10 compounds of the present invention show a dose dependent decrease relative to vehicle.

BEST AVAILABLE COPY




5

CLAIMS

What is claimed is:

1. A compound of formula I



I


wherein

10

X and Y are independently selected from the group consisting of CH₂, N, NR⁹, C=O, C=S, S=O, SO₂, S, O, (CR⁶R⁷)_n, C(=O)-(CR⁶R⁷)_n, and C(=S)-(CR⁶R⁷)_n;

n is 1, 2, or 3;

W is selected from the group consisting of



15

L is selected from the group consisting of N, O, S, S=O, SO₂, C(O), NC(O), NC(S), OC(O), OC(S), C(NR¹⁰), C(NOR¹⁰), and a covalent bond;

Z¹, Z², and Z³ are independently selected from the group consisting of CR⁸ and N;

20

R¹ is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkylalkyl, alkenyl, alkynyl, and alkyl groups;

5 R^2 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkylalkyl, aryl, and arylalkyl groups;

R^3 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R^2
10 and R^3 may join together to form a ring containing at least two N atoms;

R^4 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R^2 and R^4 may join together to form a ring containing at least two N atoms;

15 R^5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R^4 and R^5 , together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R^3 and R^5 may join together to form a ring
20 containing at least two N atoms;


R^6 and R^7 may be the same or different, and are each independently selected from the group consisting of H, Cl, I, F, Br, OH, NH_2 , CN, NO_2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino,
25 heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;

R^8 is independently selected from the group consisting of H, Cl, I, F, Br, OH, NH_2 , CN, NO_2 , and substituted and unsubstituted alkoxy, amino,
30 alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;

5 R^9 and R^{10} are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, alkylcarbonyl, and arylcarbonyl groups; and

10 prodrugs thereof, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.

2. A compound of formula II



II


wherein

15 A is selected from the group consisting of C or CH;

X and Y are independently selected from the group consisting of CH_2 , N, C=O, C=S, $(CR^6R^7)_n$, S=O, SO_2 , O, NR^9 , S, $C(=O)-(CR^6R^7)_n$, and $C(=S)-(CR^6R^7)_n$;

n is 1, 2, or 3;

20 W is selected from the group consisting of



Z^1 , Z^2 , and Z^3 are independently selected from the group consisting of CR^8 and N;

5 L is selected from the group consisting of N, O, S, S=O, SO₂, C(O), NC(O), NC(S), OC(O), OC(S), C(NR¹⁰), C(NOR¹⁰), and a covalent bond;

 R¹ is selected from the group consisting of H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heterocyclyl, cycloalkyl, heterocyclalkyl, cycloalkylalkyl, alkenyl, alkynyl, and alkyl groups;

10 R² is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkylalkyl, aryl, and arylalkyl groups;

 R³ is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R²

15 and R³ may join together to form a ring containing at least two N atoms;

 R⁴ is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R² and R⁴ may join together to form a ring containing at least two N atoms;

20 R⁵ is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R⁴ and R⁵, together with the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R³ and R⁵ may join together to form a ring

25 containing at least two N atoms;

 R⁶ and R⁷ may be the same or different, and are each independently selected from the group consisting of H, Cl, I, F, Br, OH, NH₂, CN, NO₂, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclaminocarbonyl, and heteroarylaminocarbonyl groups;


30

- 5 R^8 is independently selected from the group consisting of H, Cl, I, F, Br, OH, NH_2 , CN, NO_2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclamino, heteroaryl, heterocyclamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclaminocarbonyl, and
 10 heteroarylaminocarbonyl groups;

R^9 and R^{10} are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocycl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, alkylcarbonyl, and arylcarbonyl groups; and

- 15 prodrugs thereof, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.

3. A compound of formula III



III

- 20 wherein

X and Y are independently selected from the group consisting of CH_2 , N, $C=O$, NR^9 , $C=S$, $S=O$, SO_2 , O, S, $(CR^6R^7)_n$, $C(=O)-(CR^6R^7)_n$, and $C(=S)-(CR^6R^7)_n$;

- wherein when X is N, then Y is not N, with the proviso that when
 25 X is N, then Y can still be NH ;

wherein when Y is N, then X is not N, with the proviso that when
 Y is N, then X can still be NH ;

wherein when X is CH_2 , then Y is not CH_2 ;

5 wherein when Y is CH₂, then X is not CH₂;


wherein when X is NH, then Y is not NH;

wherein when Y is NH, then X is not NH;

D is selected from the group consisting of N, and C;

10 L is selected from the group consisting of N, O, S, S=O, SO₂,
C(O), NC(O), NC(S), OC(O), OC(S), C(NR¹⁰), C(NOR¹⁰), and a covalent bond;

W is selected from the group consisting of



Z¹, Z², and Z³ are independently selected from the group
consisting of CR⁸ and N;

15 R¹ is selected from the group consisting of H, and substituted and
unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl,
heterocyclalkyl, cycloalkylalkyl, alkenyl, alkynyl, and alkyl groups;

R² is selected from the group consisting of H, and substituted and
unsubstituted alkyl, alkenyl, alkynyl, cycloalkylalkyl, aryl, and arylalkyl groups;

20 R³ is selected from the group consisting of H, and substituted and
unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl,
heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R²
and R³ may join together to form a ring containing at least two N atoms;

25 R⁴ is selected from the group consisting of H, and substituted and
unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl,

- 5 arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R^2 and R^4 may join together to form a ring containing at least two N atoms;

- R^5 is selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups, or R^4 and R^5 , together with
10 the nitrogen to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group, or R^3 and R^5 may join together to form a ring containing at least two N atoms;

- R^6 and R^7 may be the same or different, and are each independently selected from the group consisting of H, Cl, I, F, Br, OH, NH_2 ,
15 CN, NO_2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and heteroarylaminocarbonyl groups;

- R^8 is independently selected from the group consisting of H, Cl, I, F, Br, OH, NH_2 , CN, NO_2 , and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclylamino, heteroarylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, and
20 heteroarylaminocarbonyl groups;
25

R^9 and R^{10} are independently selected from the group consisting of H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, alkylcarbonyl, and arylcarbonyl groups; and

- 30 prodrugs thereof, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof.

- 5 4. A composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.
5. A method of treating an MC4-R mediated disease, comprising administering to a subject in need thereof, the compound according to claim 1.
- 10 6. The method according to claim 5, wherein the disease is obesity or type II diabetes.
7. A composition comprising the compound according to claim 2 and a pharmaceutically acceptable carrier.
8. A method of treating an MC4-R mediated disease, comprising administering to a subject in need thereof, the compound according to claim 2.
- 15 9. The method according to claim 8, wherein the disease is obesity or type II diabetes.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/10965

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07D 209/02, 209/44, 209/46, 209/48, 217/22, 235/24, 235/28, 277/62, 403/02; A61K 31/47, 31/425, 31/415, 31/40; A61P 7/00
US CL : 514/309, 367, 394, 395, 414, 416, 417; 546/141; 548/178, 306.1, 306.4, 307.1, 307.4, 309.4, 309.7, 466.

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : Please See Continuation Sheet

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96/04270 A1 (SYNAPTIC PHARMACEUTICAL CORPORATION) 15 February 1996 (15.02.1996).	2, 3 and 7-9
X	EP 0 354 553 A2 (E.R. SQUIB & SONS, INC.) 14 February 1990 (14.02.1990).	1, 3 and 4
X	US 4,824,835 A (MERTENS et al.) 25 April 1989 (25.04.1989).	1, 3 and 4

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

12 July 2002 (12.07.2002)

Date of mailing of the international search report

02 AUG 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Brenda L. Coleman

Telephone No. 703-308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/10965

Continuation of B. FIELDS SEARCHED Item 1:

514/309, 367, 394, 395, 414, 416, 417; 546/141; 548/178, 306.1, 306.4, 307.1, 307.4, 309.4, 309.7, 466, 467, 470, 471, 472, 473, 476, 477, 480, 481



THIS PAGE BLANK (USPTO)